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ABSTRACT 
Polycystic Kidney Disease (PKD) is the most common genetic cause of kidney failure 
in children and adults and can be inherited as an autosomal dominant trait (ADPKD) 
or an autosomal recessive trait (ARPKD). ADPKD is the most common form, 
characterized by a late onset, caused by mutation in two causative gene PKD1 and 
PKD2; while ARPKD represents the rarest and most severe form, with early onset, 
caused by mutation in PKHD1 gene. The large size, the molecular complexity, the 
lack of mutational hotspot characterizing the causative genes and, in particular, the 
high homology of PKD1 with six pseudogenes make the molecular diagnostics 
challenging, time-consuming and expensive when using conventional sequencing 
methods. 
The aim of this work is to develop and validate a rapid and cost-saving genetic test for 
the molecular diagnosis of ADPKD and ARPKD based on Next-Generation 
Sequencing (NGS) using the Ion PGMTM platform. For PKD2 and PKHD1 screening 
the standard protocol for targeted-resequencing based on Ion Ampliseq technology 
was reliable; however for the PKD1 gene a strategy based on target-preselection using 
LR-PCR was applied in order to overcome the pseudogenes issue. The method 
validation, carried out on a cohort of patients with known molecular defects, showed 
100% sensitivity and specificity. The prospective validation phase, carried out on 
different cohorts of patients with clinical suspect of ADPKD (n=125) or ARPKD 
(n=28), showed a detection rate of 90.4% and 85.7% respectively. Overall, 154 
causative mutations were detected, 84 (54.5%) of which resulted previously 
undescribed, contributing the widening of the mutational spectrum of PKD. 
In conclusion, this NGS-based genetic approach is highly accurate and reliable for 
mutation analysis, achieves a high sensitivity, a faster turnaround time and lower cost 
in comparison to conventional Sanger sequencing. 
NGS would be an appropriate new standard for clinical genetic testing of PKD. 
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1. BACKGROUND
1.1 Polycystic Kidney Disease (PKD) as Ciliopathy 
Polycystic Kidney Disease (PKD) is the most common genetic cause of kidney failure 
in children and adults. PKD is characterized by clusters of fluid-filled sacs, called 
cysts, which may arise in any part of nephron and can interfere with the kidney ability 
to filter waste products from the blood. The formation of cysts leads to the renal 
parenchyma destruction and causes renal enlargement, thereby disrupting the normal 
architecture of the kidney. Cysts may also develop in other organs, particularly in the 
liver (Wilson 2004).  
As these kinds of disorders are caused by molecular defects in genes encoding for 
particular primary cilium proteins they are classified as “Ciliopathies”. 
Primary cilium is a hair-like appendage, present in most human cells, extending from 
the cell surface into the extracellular space, acts as cellular “antennae” to sense and to 
respond to extracellular signaling molecules, thanks to over 400 different proteins 
contained within its (Badano et al 2006). In particular, in kidney epithelial cells, 
primary cilium is indispensible for solute exchange, cellular signal transduction, and 
mechanical sensor of urine flow (Rodat-Despoix et al 2009). Finally, it plays also 
crucial role during differentiation and organogenesis (Marshall et al 2006; 
Poureetezadi et al 2016). 
The term Polycystic Kidney Disease refers to two different diseases which differ in 
their mode of genetic inheritance and clinical phenotype: Autosomal Dominant 
Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease 
(Wilson 2004). 
1.1.1 Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
ADPKD (MIM #173900) is inherited as dominant trait and it is typically diagnosed in 
adults after the third decade of life with an incidence of 1:400–1,000. The disease is 
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characterized by the progressive, bilateral development and enlargement of focal cysts 
that in many cases ultimately result in end-stage renal disease (ESRD) (Torres et al 
2007) (Figure 1). 
 
A 
 
B 
 
C 
 
Figure 1: A) Cysts formation and development in an age dependent manner. The cysts development causes the progressive renal 
failure (PKD foundations 2017); B) ADPKD kidney compared with normal kidney (University of Virginia 2015); C) ADPKD 
patient renal ultrasound. The dark areas labeled with "C" represent cysts. Several smaller cysts are can also be seen (University of 
Virginia 2015). 
 
 
The relentless development and grow of cysts cause progressive kidney enlargement 
associated with hypertension, abdominal fullness and pain, sporadic episode of cysts 
hemorrhage, gross hematuria, nephrolithiasis, cysts infection and a reduced quality of 
life (Grantham et al 2006; Torres et al 2007; Chapman et al 2012). Despite continuous 
destruction of renal parenchyma, the surviving glomeruli can maintain the normal 
renal function for decades by compensatory hyperfiltration. (Grantham et al 2006). 
Only when the majority of nephrons have been compromised, renal function decline 
leading to ERSD. 
As ADPKD is a systemic disorder other organs are involved with potentially serious 
complications such as massive hepatomegaly and intracranial aneurysm (ICA) 
rupture. Additional extrarenal manifestations mainly encompass cysts in other organs 
(seminal vesicle: 40%; pancreas: 10%; arachnoid membrane: 8%; spinal meningeal: 
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2%) and connective tissue abnormalities (mitral valve prolapse, abdominal hernia, 
and diverticular disease (Torres et al 2007) (Table 1). 
 
Table 1: Extrarenal manifestation in ADPKD 
 
Extrarenal	Manifestation	 Associated	 %	Affected	
Cardiac	valve	abnormalities	 Yes	 Mitral	valve	prolapse	25%	
Pericardical	effusion	 Yes	 Up	to	35%	
Extracranical	Aneurysm	 Yes,	case	report	(Yeung	et	al.	2000)	 Unknown	
Arachonid	cysts	 Yes	 8-12%	
Spinal	meningeal	cysts	 Yes	 1.7%	
Pancreatic	cysts	 Yes	 10%	
Diverticular	disease	 Possibly	in	association	with	ERSD	 20-50%	in	ERSD	
Abdominal	hernias	 Yes	 Unknown	
Seminal	vescicle	cysts	 Yes	 40%	
Male	infertility	 Unknown	 Unknown	
Bronchiectasis	 Possibly	 37%	in	one	series	vs	13%	controls	
Congenital	hepatis	fibrosis	
Yes,	usually	affecting	only	
one	generation	within	a	
family	ADPKD	
Rare	
 
Table 1: Extrarenal clinical manifestations of ADPKD are listed in table. Abbreviations: ADPKD, autosomal dominant 
polycystic kidney disease, ERSD, end-stage renal disease (Chapman et al. 2015). 
1.1.1.1 Genetics of ADPKD 
Autosomal Polycystic Kidney Disease is caused by mutations in two different genes: 
PKD1 that accounts for 80-85% of cases and PKD2 for the remainder. ADPKD has 
strikingly high phenotypic variability; the severity of the disease can depend on the 
identity of the affected locus (PKD1 vs PKD2 mutation), the allelic variant, timing of 
gene inactivation, mosaicism, and genetic background. Mutations in PKD2 versus 
PKD1 lead too much milder disease, with average ages at ESRD of 79.7 and 58.1 
years, respectively. Milder disease is also noted in ADPKD cases associated with 
non-truncating versus truncating mutations of PKD1. However, the genotype-
phenotype relationship is not completely understood. The disease is associated with a 
variety of phenotypes, from newborn infants with massive cystic kidneys to patients 
whose kidney function persists at adequate levels well into old age (Cornec-Le Gall et 
al 2014; Rossetti et al 2007). 
A high level of allelic heterogeneity is found for both genes. A total of 2,323 different 
variants is reported for PKD1 and 278 for PKD2 in the ADPKD Mutation Database at 
Mayo Clinic (http://pkdb.mayo.edu), the most complete mutation database for 
ADPKD. The vast majority of mutations are unique to a single pedigree. For PKD1, 
1,273 (54.7%) are classified as pathogenic (nonsense (20.7%), large 
deletion/frameshift/indel/ (44.9%), missense (24.7%), splicing variant (9.7%)). For 
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PKD2 a larger proportion of mutation is represented by large deletion/frameshift/indel 
(44.9%) and nonsense (20.7%) whereas one third are missense and splicing variants 
(33.7%) (Figure 2). 
 
A 
  
B 
  
Figure 2: variants reported, up to date (2016), in ADPKD Mutation Database (PKDB) per PKD1 and PKD2, grouped by 
pathogenicity level (A) and type of pathogenic variants (B). 
A): The variants are grouped according their pathogenicity level (HLP, Higly Likely Pathogenic; DP, Definitely Pathogenic; LP, 
Likely Pathogenic; LH, Likely Hypomorphic; Ind, Indeterminate; LN, Likely Neutral; B): for all pathogenic variants are reported 
the percentage for type (Fs/Indel/LD, Framshift/Insertion Deletion/Large Deletion); Abbreviations: NS, Nonsense; MS, 
missense; SP, Splicing variant) (http://pkdb.mayo.edu). 
 
 
A positive family history is absent in 10–15% of patients with ADPKD because of de 
novo mutations, mosaicism, mild disease from PKD2 and non-truncating PKD1 
mutations, or because of unavailability of parental medical records. 
1.1.1.2 Complex inheritance pattern 
Although ADPKD is classically inherited as an autosomal dominant disease resulting 
from heterozygous mutations in either PKD1 (#MIM 601313) or PKD2 (#MIM 
173910), recent and major advances in molecular genetic basis underline complex 
inheritance pattern of ADPKD, leading to the discovery of hypomorphic or 
incompletely penetrant alleles. 
 
Homozigosity. As findings in both PKD1 and PKD2 knockout mouse suggest, 
homozygosity of PKD1 or PKD2 mutations would be embryonically lethal (Wu et al 
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2002). Consistently, the inheritance of two disease-causing PKD1 alleles from both 
consanguineous (Paterson et al 2002) and non-consanguineous (Peces et al 2008) 
affected parents caused recurrent fetal losses. However, homozygosity involving 
either PKD1 or PKD2 has been reported to be a cause of ADPKD in four unusual 
families: c.9829C>T (p.Arg3277Cys) and c.9563A>G (p.Asn3188Ser) PKD1 
homozygous mutations were each found in a consanguineous families (Rossetti et al. 
2009) and the third homozygous PKD1 mutation, comprising two cis-linked 
nucleotide changes (c.[3133G>A;4709C>T] p.[Val1045Met;Thr1570Met]) was found 
in a family with unknown consanguinity (Vujic et al 2010). A common feature of 
these variants is that they were associated with no or at most suspected PKD in the 
heterozygous state but caused a definite and often severe disease in the homozygous 
state. Therefore, each of the three mutations can be reasonably defined as 
hypomorphic (Vujic et al 2010). 
 
Compound heterozygosity. More compound heterozygotes ADPKD cases are 
known than homozygotes, and all involve the PKD1 gene. These observations can be 
accounted for by (i) the much larger contribution of PKD1 to the disease compared 
with PKD2 and (ii) the high allelic heterogeneity of PKD1 mutations. The reported 
compound heterozygotes (Table 2) can be divided into two categories: (i) either of the 
variants alone was associated with no or at most suspected disease but together caused 
a severe disease; (ii) one variant was a definite pathogenic mutation while the other 
was not associated with the disease alone but if coinheritance occurs the disease 
severity. The variants associated with no disease by themselves, in both categories, 
may be defined as hypomorphic. However, their roles in disease pathogenesis are 
context-dependent. Thus, although the variants in first category may be defined as co-
causative, those in the second one may be better described as disease-modifying. 
 
Trans-Heterozygousity. To date, the only known digenic inheritance involving 
PKD1 and PKD2 genes was reported in a unique multigenerational family with 
ADPKD (c.2159delA (p.Asn720fs) in PKD2 and c.1583A>G (p.Tyr528Cys) in 
PKD1). The heterozygous PKD1 p. Tyr528Cys carriers were shown to have a 
uniformly mild renal disease similar to the heterozygous PKD2 p.Leu736* carriers. 
The two trans-heterozygotes lead a more severe renal disease in the proband (Pei et al 
2012). 
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Table 2: compound heterozygousity found for PKD1 gene in different family 
 
Mutations	 Genotype-Phenotype	description	 References	
c.[8293C>T];[9313C>T]	
p.[Arg2765Cys];[Arg3105Trp]	
The	proband	had	multiple	cysts	consistent	with	PKD	at	11	
years.	Both	parents	(single	heterozygotes)	were	apparently	
unaffected.	
(Rossetti	et	al.	
2009)	
c.[6658C>T];[9829C>T]	
p.[Arg2220Trp];[Arg3277Cys]		
The	two	compound	heterozygous	children	had	in	utero	onset	
PKD.	Renal	ultrasounds	of	the	single	heterozygous	parents	
(father	at	the	age	of	41	and	mother	at	the	age	of	34)	found	
no	abnormalities.	
(Vujic	et	al.	
2010)	
c.[3820G>A];[3820G>A;8716G>
A]	p.[Val1274Met];	
[Val1274Met;Gly2906Ser]	
The	three	compound	heterozygous	children	had	PKD.	Single	
heterozygous	parents	(mother,	25	years	old;	father,	29	years	
old)	had	normal	renal	ultrasound.	
(Bergmann	et	
al.	2011)	
c.[6472C>T];[9829C>T]	
p.[Gln2158∗];[Arg3277Cys]		
The	one	p.Arg3277Cys	heterozygote	(#25	years)	had	a	
negative	renal	ultrasound.	Coinheritance	with	the	definite	
pathogenic	mutation	caused	in	utero	onset	ADPKD	
(Rossetti	et	al.	
2009)	
c.[11457C>A];[8293C>T]	
(p.[Tyr3819∗];[Arg2765Cys])		
The	one	p.Arg2765Cys	heterozygote	(#25	years)	had	a	
negative	renal	ultrasound.	Coinheritance	with	the	definite	
pathogenic	mutation	caused	in	utero	onset	ADPKD	
(Rossetti	et	al.	
2009)	
c.[7915_7916ins20];[8293C>T]	
(p.[Arg2639fs];[Arg2765Cys])	
The	one	p.Arg2765Cys	heterozygote	(#36	years)	had	a	
negative	renal	ultrasound.	Coinheritance	with	the	definite	
pathogenic	mutation	caused	in	utero	onset	ADPKD.	
Coinheritance	with	the	definite	pathogenic	mutation	caused	
in	utero	onset	ADPKD.	
(Rossetti	et	al.	
2009)	
c.[8259C>G];[6763C>T]	
(p.[Tyr2753∗];[Arg2255Cys])	
Three	p.Arg2255Cys	heterozygotes	were	associated	with	no	
or	suspected	disease.	Coinheritance	with	the	definite	
pathogenic	mutation	caused	a	more	severe	disease.	
(Bergmann	et	
al.	2011)	
c.[4051_4052delGG];[8087T>G]	
(p.[Arg1351fs];[Leu2696Arg])	
The	one	p.Leu2696Arg	heterozygote	had	a	negative	renal	
ultrasound.	Coinheritance	with	the	definite	pathogenic	
mutation	caused	a	more	severe	disease.	
(Bergmann	et	
al.	2011)	
c.[4199delT];[12413G>A]	
(p.[Leu1400fs];[Arg4138His])		
The	p.Arg4138His	heterozygote	had	a	negative	renal	
ultrasound.	Coinheritance	with	the	definite	pathogenic	
mutation	caused	a	more	severe	disease.	
(Bergmann	et	
al.	2011)	
c.[3312dupC];[6749C>T]	
(p.[Val1105fs];[Thr2250Met])	
The	one	p.Thr2250Met	heterozygote	had	a	negative	renal	
ultrasound.	Coinheritance	with	the	definite	pathogenic	
mutation	caused	a	more	severe	disease.	
(Reiterova	et	
al.	2013)	
c.[8362_8363ins34];[5848G>A]	
(p.[Ser2788fs];[p.Val1950Met])	
The	one	p.Val1950Met	heterozygote	had	a	negative	renal	
ultrasound.	Coinheritance	with	the	definite	pathogenic	
mutation	caused	a	more	severe	disease.	
(Gilbert	et	al.	
2013)	
Table 2: all compound heterozygous cases known are shown. The mutation nomenclature follows the format indicated in the 
website http://www.hgvs.org/mutnomen/. The DNA mutation numbering system is based on cDNA sequence with a “c.” symbol 
before the number, using +1 as the A of the ATG translation initiation codon in the reference sequence. Reference sequences: 
NM_001009944.2 (PKD1) (Cornec-Le Gall et al. 2014). 
 
Triallelic Inheritance. Only one patient was found to carry the PKD2 c.1445T>G 
(p.Phe482Cys) homozygous variant and a de novo heterozygous PKD1 splice-site 
mutation, c.8017-1delAG (Dedoussis et al 2008). The PKD2 p.Phe482Cys variant is 
not a common polymorphism and functional studies revealed a lower PC-2 channel 
function compared with controls in homozygous cells and heterozygous as well. As 
the patient appeared to have earlier ERSD, the PKD2 variant was considered to have a 
modifier role in this particular context (Dedoussis et al 2008). 
 
Coinheritance of mutations in one of the ADPKD genes and an additional PKD-
causing gene. A recent report shows the coinheritance of mutations in one of the two 
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ADPKD causative genes and in PKHD1 or HNF1β gene in four families (Bergmann 
et al 2011). Mutations in the HNF1β gene cause autosomal dominant “renal cysts and 
diabetes syndrome” (Horikawa et al 1997) and homozygous mutations in the PKHD1 
gene are associated with autosomal recessive polycystic kidney disease (ARPKD) 
(Mucher et al 1994). In these families the coinheritance of mutations in PKD1 o 
PKD2 genes and in an additional PKD-causing gene seems to be associated with early 
and severe renal phenotypes. 
1.1.1.3 PKD1 and PKD2 genes 
PKD1 (16p13.3) is a very large gene consisting of 46 exons span over 52 kb of 
genomic DNA and it’s characterized by GC-rich regions (62,4%), with a CpG/GpG 
ratio of 0,485 (The American PKD1 Consortium 1995). The 3’-end of the gene 
partially overlaps with 3’-end of TSC2 (#MIM 191092) gene in a “tail-to-tail” 
orientation. Contiguous deletions removing both of the tails of PKD1 and TSC2 genes 
cause a severe form of infanitile polycystic kidney disease (Sampson et al 1997). 
Moreover, the PKD1 region encompasses 5’ to 33 exon is replicated in six 
pseudogenes, expressed as mRNA transcript but not translated, mapping proximally 
on chromosome 16 (International Polycystic Kidney Disease Consortium 1994). 
These six pseudogenes differed from the genuine gene by deletion and other 
rearrangement, but share 98% sequence similarity in exonic sequences (Bogdanova et 
al 2001).  
PKD1 real gene encodes a 14,138 bp mRNA transcript (NM_001009944.2) with a 
coding sequence of 12,912 bp that is translated into a protein composed of 4,302 
amino acids: Polycystin 1 (NP_001009944). 
PKD2 (4q21-23) is a less longer and complex gene. It consists of only 15 exons 
encoding an mRNA transcript of 5,056 bp (NM_0000297) with a coding sequence of 
2,907 bp that translated into a protein composed of 968 amino acids: Polycystin 2 
(PC2) (NP_000288). 
Polycystin 1 and 2 belong to the transient receptor potential (TRP) channel 
superfamily and are also known as TRPP1 and TRPP2, respectively. 
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1.1.1.4 Polycystin 1 - 2 and PC1/PC2 Complex 
Polycystin-1 (PC1). PC1 is a receptor-like protein, with a molecular mass of  600 
kDa (uncleaved and glycosylated).  
It is expressed in epithelial cells of the differentiating and mature renal 
tubules, as well as in a variety of somatic tissues including liver, bone, heart 
and endocrine glands (Ward et al 1996; Ibraghimov-Beskrovnaya et al 1997). At 
cellular level, the protein localizes in primary cilium, as well as to the lateral 
domain of the plasma membrane and in adhesion complexes in polarized 
epithelial cells (Ibraghimov-Beskrovnaya et al 2000).  
Despite the 3D structure remains unresolved because the protein size and complexity, 
many study focused only on isolated domain to try to understand the protein modular 
structure. The current view of the protein is shown in Figure 3.  
The large extracellular domain comprises a number of domains involved in protein-
protein and protein-carbohydrate interactions. The Leucine-Rich repeat (LRR) 
domain (N-terminus) is followed by sixteen immunoglobin-like domains named PKD 
repeats, a receptor for egg-jelly (REJ) domain and a GPCR-Autoproteolysis Inducing 
(GAIN) domain. The first PKD domain is separated from the other 15 by a c-lectin 
type domain. The PKD domain is reminiscent of proteins with structural and 
mechanic role, as fibronectin, and may mediate the formation of multicellular 
structures. The GAIN domain includes G protein-coupled receptor proteolysis site 
(GPS) motifs that mediates cis-autoproteolysis of PC1 to generate a 320 kDa N-
terminal product and a 140kDa C-terminal non-covalently bound. The role of auto-
proteolytic cleavage is not completely understood yet but several studies suggest that 
may be important during cellular development (Chapin et al 2010; Yu S 2007). 
Functional studies demonstrates the role of the entire extracellular domain in 
mediating cell adhesion and/or cell junction formation via trans-homophilic 
interactions of PKD domains and cis-heterophilic interactions with E-cadherin 
(Streets et al 2009). The PC1 is anchored to the cellular membrane by eleven 
transmembran domain. In the intracytoplasmatic portions are located the Polycystin-1 
Lipoxygenase Alpha-Toxin (PLAT) domain and the C-terminal tail. PLAT domain is 
considered a signature domain of PKD1-like protein and represents a lipid/protein-
binding scaffold to integrate cell signaling and PC1 traffiking. The C-terminal tail is 
the best studied region and contain a coiled-coil domain for PC2 binding and a G-
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protein binding and activation sequence. It can bind many phosphatases which 
regulates PC1 and PC2 phosphorilation and other key signaling proteins or effectors 
as mTOR, Wnt, JAK/STAT) (Shillingford et al 2006; Lal et al 2008; Bhunia et al 
2002). 
 
Polycystin-2 (PC2). PC2 is a high conductance non-selective Ca2+ permeable channel 
with a molecular mass of  ~110 kDa. Although a portion of PC2 colocalizes with PC1 
to the cilium, the majority of the PC2 is found in intracellular calcium stores where 
regulates the release of this cation in response to local increase in Ca2+ concentrations 
(Vassilev et al 2001; Koulen et al 2002).  
Polycystin 2 consists of six transmembrane domains, which partially share 
homologies with PC1 TM domain, comprised between the C-N terminal domains 
(Figure 3).  
The calcium-conducting pore is formed by the loop between the fifth and the sixth 
transmembrane domains (Koulen et al 2002). The C-terminal domain contains two 
coiled-coil domains (CT1 and CT2) and an EF-hand domain. CT1 is essential for 
recognition and binding of the PC1 C-terminus to form a PC1/PC2 complex, whereas 
the CT2 mediates the oligomerization between different PC2s to form oligomeric 
complexes. The EF-hand domain is a helix-loop-helix structures with a Ca2+-binding 
site that permits to sense or buffer changes in calcium concentration (Gifford et al 
2007). Slightly overlapping with both coiled-coil and EF-hand is one of the two 
membrane targeting motifs required to maintain the PC2’s ER and Golgi localization, 
the other one is in N-terminal portions and is required to guides and maintain ciliary 
localization (Cai et al 1999). 
  
PC1/PC2 complex. PC1 and PC2 form a heteromeric molecular complex in cilia, 
with PC1 serving as a mechanosensor and PC2 functioning as a Ca2+ channel. 
Changes in urinary flow in extracellular space lead to the bending of cilia and PC1-
PC2 complex-dependent Ca2+ entry into cell resulting in measurable increases in 
cytosolic calcium concentration. This flow-mediated increase in cell calcium is 
diminished if either PC1 or PC2 are absent or nonfunctional (Nauli et al 2003). 
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Figure 3: Predicted structures of Polycystin 1 (PC1) and Polycystin 2 (PC2): PC1 is a receptor-like protein with a large 
ectodomain, 11 transmembrane domains and a cytoplasmic tail. The last 6 transmembrane domains of PC1 are homologous to the 
transmembrane region of PC2. PC2 is a transient receptor potential–like calcium channel that has an EF-hand motif and an 
endoplasmic reticulum (ER) retention signal in the carboxy (C) terminus and a proposed cilia targeting sequence in the amino (N) 
terminus. PC1 and PC2 physically interact through coiled-coil domains in the cytoplasmic tail of PC1 and in the carboxy-terminal 
tail of PC2 (Ong et al 2015). 
 
1.1.1.5 Signalling pathway modified by PC1 and PC2  
Polycystins protein modulates several pathways most of them implied in cellular 
differentiation, growth, division, apoptosis and planar cell polarity determination. 
Alteration in these pathways may activate the cystogenesis process. Misregulating 
PC1 and PC2 expression or PKD1 cleavage appears to result in aberrant signaling, 
which may in turn lead to the abnormal cellular growth behaviors that are likely to 
contribute to ADPKD pathogenesis. The major involved signaling pathways are 
negative growth regulation, G protein activation, and Wnt pathway modulation 
(Figure 4). 
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Figure 4: PC1 and PC2 affect multiple signaling pathways. Summary of the effects that PC1 and PC2 exert on signaling 
pathways. Multiple direct and indirect interactions allow the polycystin proteins to inhibit or stimulate pathways involved in 
cellular growth and differentiation (Chapin H.C 2010). 
G-Protein activation. PC1 functions as a G-protein coupled receptor (GPCR), as 
contains sequences that are found in GPCRs (Igarashi et al 2002). Downstream 
signaling through GPCRs can lead to the activation of c-Jun N-terminal kinase (JNK) 
and activator protein-1 (AP-1) pathways that can regulate cell proliferation, 
differentiation, cell cycle, apoptosis and inflammation.  
 
Growth regulation. The mechanisms utilized by PC1/PC2 include signaling through 
the JAK-STAT pathway (Bhunia et al 2002). Signaling through this pathway leads to 
the activation of STAT1 and STAT3, subsequent upregulation of the cyclin-
dependent kinase inhibitor (CKI) p21, and the inhibition of cyclin dependent kinase 2 
(CDK2) which ultimately leads to cell cycle arrest at the G0/G1 transition (Li et al 
2005). Additional evidence for a direct role of polycystins in cell cycle regulation was 
shown by the direct interaction of PC2 with the helix-loop-helix (HLH) protein Id2, 
which regulates cell proliferation and differentiation. Phosphorylation of PC2 by PC1 
leads to its interaction with Id2-E47 complex. The interaction of the Id2-E47 complex 
with PC2 sequesters this complex outside the nucleus. When PC2 is unable to bind to 
this complex, Id2 is translocated to the nucleus and exerts its dominant negative 
effects on E47 and other HLH proteins. In this manner, the normal expression of PC1 
and PC2 leads to cell cycle arrest by an increase in p21 while a mutation in one of the 
polycystins leads to the dysregulation of this pathway resulting in increased cell 
proliferation (Low et al 2006). 
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An additional significant effect of PC1 involves inhibition of the mTOR(mammalian 
target of rapamycin) cascade which regulates protein translation, cell proliferation, 
and cell growth (Shillingford et al 2006). Normally TSC1 and TSC2 (tuberous 
sclerosis 1 and 2) complex acts as a negative regulator of the mTOR complex (Huang 
et al 2008) and Shillngfors et al showed that PC1 C-terminal tail interacts with TSC2 
stabilizing the functional TSC1– TSC2 complex. In the absence of a functional PC1, 
as in most cases of ADPKD, the mTOR pathway is activated (Shillingford et al 2006). 
 
Wnt-Pathway. ADPKD cysts and PC1-null cells manifest up-regulation of Wnt 
signaling activity markers, suggesting that PC1 exerts a negative effect on this 
system. The Wnt pathways affect growth, differentiation, and establishment of planar 
cell polarity. In the canonical pathway, the presence of the Wnt ligand induces β-
catenin stabilization and nuclear translocation, leading to T cell factor (TCF)–
dependent transcriptional activity. Cleaved PC1 CTT inhibits this pathway by directly 
or indirectly binding to β-catenin, moving with it to the nucleus, and reducing its 
ability to promote TCF-dependent transcription (Lal et al 2008). PC2 may also 
regulate the expression of some components of the Wnt pathway. Knocking out PC2 
in cultured mouse cells resulted in increased levels of β-catenin protein (Kim et al 
2009). 
PC1 may also regulate noncanonical Wnt signaling, which is in turn related to the 
maintenance of planar cell polarity. The cells lining renal tubules generally divide 
parallel to the tubule’s axis, lengthening the tubule rather than expanding its diameter. 
Tubule-lining cells in models of polycystic kidney disease, however, show a tendency 
to divide at an angle to the tubule’s axis, which could lead to expansion of the tubule 
diameter. This deviation can occur before cysts appear, suggesting that a loss of this 
planar cell polarity may be a precursor to cyst formation (Fisher et al 2006; Patel et al 
2008).  
A disruption in the switch between canonical and non-canonical Wnt signaling could 
be involved in cystogenesis process (Fisher et al 2006). 
1.1.1.6 Cysts formation 
Cysts form as small dilations in renal tubules, which then expand to form fluid-filled 
cavities of different sizes. Factors that are thought to lead to cystogenesis include a 
germ-line mutation in one of the polycystin gene alleles, a somatic second hit which 
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leads to the loss of the normal allele, and a third hit, which can be anything that 
triggers cell proliferation, leading to the dilation of the tubules. Continued dilation of 
the tubules through increased cell proliferation, fluid secretion, and separation from 
the parental tubule will lead to the formation of cysts. Other factors that are involved 
in cystogenesis and/or cyst progression include defective planar cell polarity, 
extracellular matrix abnormalities, inflammation, increased apoptosis, modifying 
genes, and environmental factors (Igarashi et al 2002). 
1.1.2 Autosomal Recessive Polycystic Kidney disease (ARPKD) 
ARPKD (#MIM 263200) is inherited as recessive trait and belongs to a group of 
congenital hepatorenal fibrocystic (CHF) syndromes and is a cause of significant 
renal and liver-related morbidity and mortality in children. It is more rare than 
ADPKD with an incidence of 1-20.000 live births and the carrier frequency in the 
general population was estimated at 1:70 (Zerres et al 1998), therefor, the risk of 
ARPKD in offspring of a proband is approximately 0,7%. Rare milder forms are also 
known in adolescents and adults. 
In infancy, the disease results in significantly enlarged echogenic polycystic kidneys, 
with pulmonary hypoplasia resulting from oligohydramnios as a major cause of 
morbidity and mortality. Renal failure is rarely a cause of neonatal demise. On 
sectioning of the enlarged kidney, fusiform dilatations arranged radially through the 
renal parenchyma from medulla to cortex are seen, with rounded cystic dilatations in 
the medulla. Liver involvement is detectable in approximately 45% of infants and is 
often the major feature in older patients (Harris et al 2004) (Figure 5).  
 
A 
 
B 
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Figure 5: Baby with autosomal recessive polycystic kidney disease (ARPKD). A) Distended abdomen due to voluminous 
kidneys that lead to respiratory problems; B): nephrectomized kidney of this girl; C) - D) Ultra-sound showed symmetrically 
enlarged echogenic kidneys with fusiform dilations of collecting ducts and distal tubules arranged radially throughout the renal 
parenchyma from medulla to cortex (Bergmann et al 2011). 
 
In ARPKD patients surviving the neonatal period, have as much as 80% chance of 
living to more than 15 years of age (Kaplan et al 1989). Advances in neonatal 
intensive care and renal replacement therapies have improved the survival rates of 
ARPKD patients, with some of them reaching adulthood. However, life expectancy is 
severely diminished and a wide range of associated comorbidities often evolve, 
including systemic hypertension (HTN), endstage renal disease (ESRD), and clinical 
manifestations of congenital hepatic fibrosis (CHF) (Roy et al 1997). ARPKD is 
invariably associated with biliary disgenesis and the Caroli’s disease is often 
observed. 
The most severely affected fetuses have enlarged echogenic kidneys and display a 
“potter” oligohydramnios phenotype with pulmonary hypoplasia, a characteristic 
facies, and contracted limbs with clubfeet (Roy et al 1997). The only signs potentially 
detectable in utero are enlargement and increased echogenicity of both kidneys. 
Improved respiratory treatment leads to increase neonatal survival, but death still 
occurs in the neonatal period in approximately 25%-30% of affected individuals 
primarily because of respiratory insufficiency (Kaplan et al 1989; Roy et al 1997). 
Liver involvement is always present and may be the predominant clinical extrarenal 
feature; in some of these cases, renal ultrasonography may be required to detect 
clinically silent renal disease. Complications of the hepatic disease include portal 
hypertension induced by hepatic fibrosis (Alvarez 1981) and acute bacterial 
cholangitis associated with dilatation of the bile ducts (Kääriäinen et al 1988). Results 
of liver function tests usually remain within the normal range. Ultrasonography of the 
liver reveals dilatation of the peripheral intrahepatic ducts and the main bile ducts. 
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Hepatic cysts may be present and there may also be signs of portal hypertension. 
Magnetic resonance cholangiography, a non-invasive imaging technique, can also 
visualize non-obstructive dilations of the intrahepatic bile ducts (Jung et al 1999).  
Approximately 50% of affected individuals progress to end stage renal disease 
(ESRD) within the first decade of life. (Roy et al 1997). Hypertension may occur in 
up to 80% of children with ARPKD, it is frequently severe and is generally correlated 
with decrease in renal function. Therapies with an angiotensin converting enzyme 
inhibitors or ATII receptor inhibitors are generally effective (Guay-Woodford et al, 
2003; Kaplan et al 1989). Additional clinical complications include nephrogenic 
diabetes insipidus, failure to thrive, and hyponatremia (Dell et al 2004; Guay-
Woodford et al 2003; Zerres et al 1996). 
1.1.2.1 Genetics of ARPKD 
ARPKD is caused by mutations affecting PKHD1 (MIM* 606702) gene. Up to date, 
the major mutation database that collects and classifies all described PKHD1 variants, 
associated to ARPKD clinical phenotype, is Humgen (http://www.humgen.rwth-
aachen.de) (Figure 6). Of all mutant alleles found 49% are single nucleotide missense 
substitutions, about 12% are small deletions, insertions, or duplications, 
approximately 9% contain nonsense mutations, and a few mutations (30%) affect the 
canonical splice site sequences. 
 
Figure 6: The pie chart reports the percentage (%) of variants, described up to date (2016), in Mutation Database Autosomal 
Recessive Polycystic Kidney disease (ARPKD/PKHD1).  
 
Thus far, gross genomic rearrangements (deletions/ insertions/ inversions), promoter 
alterations or mutations in alternatively spliced exons not included in the longest 
ORF, have not yet been encompassed into the analysis in most of the studies.  
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The most common pattern of mutations in ARPKD patients is two different changes 
(compound heterozygotes) (Onuchic et al 2002; Ward et al 2002; Bergmann et al 
2004; Furu et al 2003; Rossetti et al 2003). Indeed, it is possible that some rare 
‘‘polymorphisms’’ may be mutagenic when found in combination with an 
inactivating mutation. As a wide range of compound heterozygous changes are 
associated with ARPKD, it has been difficult to determine clear genotype/phenotype 
correlations. In different studies, affected families were categorized by clinical 
presentation into ‘‘severe’’ and ‘‘moderate”: the ‘‘severe’’ cohort comprised families 
in which at least one affected child presented with perinatal disease and neonatal 
demise, while the ‘‘moderate’’ group included families in which affected patients 
either survived complications during the first month of life or first became 
symptomatic beyond the neonatal period. Thanks to this classification it was seen that 
in the moderate cohort, missense changes were more than two times as frequent as 
chain-terminating alterations, whereas the compound heterozygosis of Loss of 
Function (LOF) mutations caused severe phenotype.  
1.1.2.2 PKHD1 gene 
PKHD1 (6p12) gene is the only candidate gene for all typical forms of ARPKD. 
PKHD1 extends over 469 kb and include a minimum ok 86 exons (Onuchic et al 
2002; Ward et al 2002). The longest PKHD1 transcript includes 67 exons (Figure 7) 
with an open reading frame (ORF) composed of 66 exons that encode a 4074 amino 
acid protein, polyductin/fibrocystin. Alternatively spliced transcripts are predicted to 
fall into two broad groups. The first subset, polyductin-M, is comprised of 
polypeptides that contain the single TM element but vary with respect to inclusion of 
the other predicted domains. The second subset, polyductin-S, lacks the TM domain 
and thus its members may be secreted (Onuchic et al 2002).  
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Figure 7: PKHD1 gene structure. The gene has 86 exons so far identified; 71 are non-overlapping while 15 are exons with 
alternative splicing boundaries (A and B). The putative longest open reading frame (ORF) transcript comprises 67 exons (A). 
Preliminary analyses suggest that PKHD1 encodes a high number of alternative transcripts. Two examples of differential 
assembling are shown at the bottom of the figure (C). SC: approximate location of the stop codon; dark gray: alternative exons; 
light gray: noncoding exons in the corresponding transcripts (Menezes et al.2006). 
1.1.2.3 Fibrocystin 1/Polyductin (FC1) 
The PKHD1 protein, Fibrocystin 1/Polyductin (FC1), is predicted to have 4074 amino 
acids (4059 amino acids in the mouse) with a calculated unglycosylated molecular 
weight of 447 kDa (Ward et al 2002; Onuchic et al 2002). However, the mature 
protein may be significantly larger as there are multiple potential N-linked 
glycosylation sites. Fibrocystin has a signal peptide, and structural predictions 
indicate a large extracellular region (3860 aa) with multiple copies of the TIG domain 
(an immunoglobulin-like fold), domains that shared homology with TMEM protein of 
unknown function, several parallele b-helix (PbH), a single transmembrane region 
and a short cytoplasmic tail (192 aa) (Ward et al 2002) (Figure 8). The role of other 
TIG containing proteins, such as the hepatocyte growth factor receptor (Met) and the 
plexins, and the structure of fibrocystin, suggest that it may be a receptor protein 
(Ward et al 2002). PbH1 repeats are present in virulence factors, adhesins, and toxins 
in bacterial pathogenesis and known to bind to carbohydrate moieties (Cowen et al 
2002). Several secreted forms of fibrocystin may also be generated from alternatively 
spliced transcripts (Ward et al 2002; Onuchic et al 2002). 
The external region also contains 64 potential N-glycosylation sites, suggesting that 
the protein may be highly glycosylated. In addition, FC1 short carboxylic tail includes 
putative cAMP/cGMP-dependent protein kinase phosphorilation sites (PKA and 
PKC) (Ward et al 2002). 
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Figure 8: Predicted structure of FC1, a large integral membrane protein, 4074-amino-acid The structure of FC1 as an integral 
membrane protein with a large extracellular portion and a short intracellular C-terminal suggest that this protein acts as a 
transducer of extracellular information into the cell by eliciting signal transduction cascades resulting in the modulation of gene 
transcription (Ward et al. 2002). 
 
The function of FC1 is not known, but the structure and homologies suggest a role as 
a receptor protein possibly involved in modulating the terminal differentiation of 
collecting ducts and the biliary system. 
Immunohistochemistry analyses revealed staining of cortical and medullary collecting 
ducts and thick ascending limbs of Henle in kidney and biliary and pancreatic duct 
epithelia. In human fetus and mouse developing tissues, staining was observed in the 
branching ureteric bud but not in the metanephric mesenchyme, S-shaped bodies or 
glomeruli (Menezes et al 2006). 
Several studies have shown that at the subcellular level FC1 is expressed in primary 
apical cilia in kidney cells and cholangiocytes (Menezes et al 2004; Ward et al 2003; 
Wang et al 2004). 
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Immunoreactive FC1 localized at the apical domain of polarized epithelial cells, 
suggesting it may be involved in the tubulogenesis and or maintenance of duct–lumen 
architecture. FC1 is localized at the apical membrane in collecting duct cells and in 
the cytoplasm of inner medullary collecting duct (IMCD) cells grown in culture 
(Menezes et al 2006). 
 
1.1.2.4 Polycystin complex and Fibrocistin/Polyductin interaction 
PC2, one of the two ADPKD protein involved in calcium signaling, was seen to 
participate in an indirect way at the same protein complex with FC1 (Figure 9). 
The linker protein involved in the creation of a triplex (PC2–KIF3B–FC1) is the 
kinesin-2 motor subunit KIF3B. Moreover, several experiments demonstrated that 
PC2 and FC1 are in the same complex only if KIF3B is present; altering KIF3B level 
in IMCD cells by over-expression or by siRNA significantly affected complexing 
between PC2 and FC1 (Wu et al 2006). 
Thus, KIF3B represents the first molecular linker between ADPKD and ARPKD 
proteins, suggesting that the protein complex PC2–KIF3B–FC1 is part of a common 
molecular pathway implicated in renal cystic diseases. Kinesin-2, as a heterotrimer 
formed by KIF3A, KIF3B and KAP3, is important for numerous cell functions, in 
particular, cilium growth and cell cycle (Miki et al 2001; Cole 1999) and has 
profound pathological implications. In ciliated IMCD cells, PC2 partially co-localized 
with KIF3B and FC1 in primary cilia suggesting the possibility that the flow sensor is 
composed of a larger complex containing not only PC1 and PC2, but also KIF3B, 
FC1 and possibly other proteins (Wu et al 2006). 
FC1 is capable of increasing PC2 channel function in the presence, but not in the 
absence, of KIF3B. Thus, KIF3B likely links PC2 and FPC together not only in a 
structural complex, but also for the regulation of PC2 channel function. So, FC1 is 
another partner of PC2, which functionally upregulates its channel function through 
KIF3B regulations. 
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Figure 9: Mechanosensory protein complex. Among other subcellular localizations, it is thought that polycystin-1, polycystin-2 
and fibrocystin form a mechanosensory complex protein in the cilium to sense fluid-shear stress. Polycystin-1 and polycystin-2 
interact with each other at their COOH termini forming a polycystin complex that interacts with Fibroystin1/Polyductins via Kif 
as linker protein. (Kolb et al 2008) 
 
It is also possible that the roles that KIF3B plays in the PC2–FC1 complexing and in 
the modulation of PC2 by FC1 are different from its role as a kinesin-2 motor subunit. 
(Wu et al 2006). 
Unlike the biliary ductal epithelial cells (Masyuk et al 2004), however, successful, but 
not total, reduction of FC1 in the RNA and protein levels did not result in obvious 
defects in ciliogenesis, suggesting that the residual FC1 is sufficient for normal 
ciliogenesis or there might be other specific splicing events of PKHD1 (Onucich et al 
2002).  Evidences show that the disruption of either FC1 or the PC1/PC2 complex at 
the primary cilium results in defects in mechanosensation of fluid flow (Wang et al 
2007). 
1.1.3 Ultrasonography in ADPKD and ARPKD diagnosis  
Ultrasonography (US) is the diagnostic method of choice for assessing ARPKD and 
ARPKD because it is cost effective, painless, widely available, and does not require 
radiation or sedation.  
Typical imaging findings from patients with ADPKD reveal large kidneys with 
multiple bilateral cysts. Important factors in diagnosing include family history of 
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ADPKD, age of patient, and number of kidney cysts. Age-dependent ultrasound 
criteria for both diagnosis and disease exclusion have been established for patients 
with a positive family history. If ultrasonography results are equivocal, magnetic 
resonance imaging (MRI) or computed tomography (CT) may clarify the diagnosis 
(Pei et al 2015). In the absence of a family history, these imaging-based criteria do not 
apply. In several situations, multiple factors should be considered, including the age 
of the patient, the presence of additional associated manifestations, and findings or 
family history suggestive of other genetic disorders. ADPKD is the most likely 
diagnosis in the presence of bilaterally enlarged kidneys and innumerable cysts in 
each kidney, therefore other genetic diseases can be associated with kidney cysts so, 
when suggestive findings are noted, the differential diagnosis should be broadened 
(Pei et al 2015). 
During the pregnancy it may be possible to detect ARPKD during the usually 
ultrasound scans routine. The kidneys of a baby with ARPKD may appear unusually 
large or bright on the scan. Early signs of ARPKD are sometimes visible during the 
first routine ultrasound scan carried out at week 12 of pregnancy, although the 
condition isn't usually detected until the second routine scan at around 20 weeks. US 
may demonstrate echogenic, enlarged, reniform kidneys, oligohydramnios, or an 
empty urinary bladder in severe cases of ARPKD (Turkbey et al 2009; Sweeney et al 
2011). Severely affected fetuses with oligohydramnios may have pulmonary 
hypoplasia and high mortality due to pulmonary insufficiency, or multiple intrauterine 
compression anomalies of lethal Potter sequence. The presence of large reniform 
echogenic kidneys with poor corticomedullary differentiation and oligohydramnios on 
prenatal ultrasound examination suggests ARPKD, although other diagnoses are 
possible. 
In infant and child the findings on renal imaging are noted as above and renal size 
may actually decrease with age as fibrosis progresses (Turkbey et al 2009). 
1.1.4 Genetic testing 
Genetic testing is not always required for diagnosis but may be helpful when imaging 
results are uncertain, i.e. in all that cases in which clinical phenotype overlaps with 
other syndromic renal cystic forms. Moreover a molecular diagnosis is required to 
identify living related kidney donors, or in atypical cases (e.g., early and severe 
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polycystic kidney disease, kidney failure without significant enlargement of the 
kidneys, marked discordant disease within family, marked asymmetry in disease 
severity between kidneys, or very mild PKD). Genetic testing is also useful in the 
diagnosis of sporadic PKD with no family history. Such testing can be helpful in 
reproductive counseling as well. This can be followed by multiplex-dependent probe 
amplification in cases with negative DNA sequencing results (Zerres et al 1998). The 
large size, molecular complexity, lack of mutational hotspot characterizing the 
causative genes and, in particular, the high homology with six psudogene for the first 
33 exons of PKD1 gene make the molecular diagnostics challenging.  
 Currently, the most common method used for molecular diagnosis of ADPKD and 
ARPKD is direct mutation screening by Sanger sequencing of the PKD1 PKD2 and 
PKHD1 genes respectively (Audrézet et al 2012, Bergmann et al 2004, Bataille et al 
2011).  
1.2 From Sanger sequencing to Next-Generation Sequencing 
1.2.1 Sanger sequencing, the conventional sequencing method 
Sanger sequencing, also called the chain-termination method, was developed by 
Frederick Sanger and colleagues in 1977 (Sanger et al 1977). It is a technique for 
DNA sequencing based upon the selective incorporation of chain-terminating 
dideoxynucleotides (ddNTPs) by DNA polymerase during in vitro DNA replication. 
Classical Sanger sequencing requires a single-stranded DNA template, a DNA 
polymerase, a DNA primer, normal deoxynucleosidetriphosphates (dNTPs), and 
modified nucleotides (ddNTPs) that terminate DNA strand elongation. These ddNTPs 
lack a 3′-OH group that is required for the formation of a phosphodiester bond 
between two nucleotides, causing the extension of the DNA strand to stop when a 
ddNTP is added. The DNA sample is divided into four separate sequencing reactions, 
containing all four of the standard dNTPs (dATP, dGTP, dCTP, and dTTP), the DNA 
polymerase, and only one of the four ddNTPs (ddATP, ddGTP, ddCTP, or ddTTP) for 
each reaction. After rounds of template DNA extension, the formed DNA fragments 
are separated by size using gel electrophoresis in four parallel lanes representing ddA, 
ddT, ddC, and ddG terminators. The shortest sequences are moved further down to 
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the bottom of the gel and the reading can be achieved from the bottom to the top 
(Figure 10). 
 
Figure 10: A complementary primer anneals to a 3’ single-stranded template to start the extension of the template by adding 
dNTPs using polymerase enzyme. Equal amounts of the reaction mixture are placed into four tubes, and four ddNTPs are added 
to each tube, which terminate the sequence synthesis. The contents of the reaction tubes are then subjected to four lanes of 
polyacrylamide electrophoresis gel and the oligonucleotide sequences are separated according to the size and type of nucleotides. 
The smallest sequences are moved further down to the bottom of the gel, while the biggest sequences are remained at the top of 
the gel. The reading can be carried out from the bottom to the top as depicted with the blue arrow. Adapted from (Mardis, 2013).  
In 1986, a company named Applied Biosystems began to manufacture automated 
DNA sequencing machines based on the Sanger method. These machines used 
fluorescent dyes to tag each nucleotide, allowing the reactions to be run in one 
column and read by color during the capillary elettrophoresis (Prober et al 1987). In 
newer dye terminator sequencing, the ddNTPs are labeled with fluorescent dyes to 
make the fragments readable through a laser light source at unique wavelengths in 
capillary gels, rather than on traditional gels. Sequencers based on Sanger sequencing 
produce a read length (the length of a DNA fragment that can be sequenced at one 
time) of 800–1000 bp. Because at one time only one read can be sequenced in one 
capillary of the sequencer, the total output of the run is equal to the read length. 
However, sequencers with multiple capillaries enable one to sequence multiple 
samples at a time (e.g. 8, 16, 48, or 96, etc.). The automation of 96 or 384 
independent capillaries was designed to increase the throughput and facilitate 
sequencing of more samples (Shendure et al 2008). Furthermore, the read length of 
sequencing can be achieved by Sanger sequencing up to around 1000 bp and a high 
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level of accuracy of 99.999% can be obtained. Interestingly, Sanger sequencing was 
used in sequencing the entire human genome in the Human Genome Project (HGP) 
(Bentley 2000). The sequencing of five individuals, around 14.8 billion bp, took over 
nine months (Venter et al 2001). Therefore, the requirement of new platforms to 
provide rapid sequencing at an affordable price was needed in order to obtain the 
benefits of the sequencing.  
1.2.2 Next-Generation Sequencing technology 
Over the past 10-12 years, the advent of Next-Generation sequencing (NGS) 
techniques has dramatically increased the speed and reduced the costs of sequencing. 
The growing adoption of NGS technology and the integration of sequencing standards 
into laboratory practices may make NGS the new gold standard for clinical routine.  
In contrast to Sanger sequencing, NGS uses a different principle in its mode of action. 
In all NGS platforms, following the extraction of the genetic materials, a sequencing 
library is prepared. Initially, the sequencing library is constructed by shearing the 
targeted DNA into small fragments, either by using enzymes or physical sonication, 
and then a ligation step takes place by attaching both ends of the fragmented DNA to 
adaptors. These adapters are universal sequences, specific to each platform, that can 
be used to polymerase-amplify the library fragments during specific steps of the 
process. The fragmented DNA along with the adaptors forms the sequencing library 
(paired end library). The sequencing library is then fixed to bead particles or solid 
surfaces, depending on the platform used, in order to prepare the sequencing template 
for clonal amplification. The clonal amplification either uses emulsion PCR or solid 
phase amplification depending on the platform used, which is performed in order to 
enrich and obtain a high number of sequencing templates to ascertain appropriate 
signal production in the sequencing reaction that is sufficient for a sensitive detection 
(Goodwin et al 2016). 
Depending on the application, various NGS methods are available to suit diverse 
study designs and objectives, including whole-genome sequencing, exome 
sequencing, and targeted sequencing. Whole-genome sequencing determines the 
entire DNA sequence, while exome sequencing analyzes only on the coding portion 
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of the genome. Targeted sequencing focuses on specific genes of interest and is the 
most commonly used NGS method in molecular pathology (Goodwin et al 2016). 
1.2.2.1 NGS platform 
The variety of NGS technology features supports the coexistence of multiple 
platforms in the marketplace, with some having clear advantages for particular 
applications over others. Currently, six sequencing platforms are available (454, 
Illumina, SOLiD, HeliScope, Ion Torrent, PacBio), whereas a couple (StarLight and 
Nanopore) are in advanced development. The most salient features of the platforms 
are described below.  
• 454 was the first commercial NGS platform acquired by Roche. 454 uses 
beads that start with a single template molecule, which is amplified via 
emPCR (emulsion PCR). Millions of beads are loaded onto a picotitre plate 
designed so that each well can hold only a single bead. All beads are then 
sequenced in parallel by flowing pyrosequencing reagents across the plate 
(http://www.454.com).  
 
• Illumina uses a solid glass surface to capture individual molecules and bridge 
PCR to amplify DNA into small clusters of identical molecules. These clusters 
are then sequenced with a strategy similar to Sanger sequencing, except only 
dye-labelled terminators are added, the sequence at that position is determined 
for all clusters, then the dye is cleaved and another round of dye-labelled 
terminators is added (http://www.illumina.com). 
 
• SOLiD uses ligation to determine sequences and until the most recent of 
Illumina’s software and reagents, SOLiD has always had more reads (at lower 
cost) than Illumina (http://www.appliedbiosystems.com). 
 
• HeliScope developed by Helicos, which was the first commercial single-
molecule sequencer. Unfortunately, the high cost of the instruments and short 
read lengths limited adoption of this platform. Helicos no longer sells 
instruments, but conducts sequencing via a service centre model 
(http://www.helicosbio.com).  
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• Ion Torrent an instrument system that detects the release of hydrogen ions, as 
a result of nucleotide incorporation, quantifying changes in pH through a 
novel coupled silicon detector. In 2010, the first early access instruments were 
deployed and Ion Torrent was purchased by Life Technologies, but it is still 
known as Ion Torrent (http://iontorrent.com). 
 
• PacBio has developed an instrument that sequences individual DNA 
molecules in real time. Individual DNA polymoerases are attached to the 
surface of microscope slides. The sequence of individual DNA strands can be 
determined because each dNTP has unique fluorescent label, immediately 
detected prior to being cleaved off during synthesis. Low cost per experiment, 
fast run times and cool factor generated much enthusiasm for this platform, 
which first early instruments were deployed in 2010 
(http://www.pacificbioscience.com).  
 
StarLight and Nanopore are the upcoming sequencing technologies aiming to longer 
read length and reduced cost per sample.  
 
• StarLight is the more extensively Life Technologies Single Molecule Real-
Team Sequencing Technology. The platform uses quantum dots to achieve 
single-molecule sequencing. DNA is attached to the surface of a microscope 
slide where sequencing occurs in similar way to PacBio. As the DNA 
polymerase can be replaced after it has lost activity, the sequencing can 
continue along the entire length of a template. The peculiar innovation is the 
ability to perform 3-Dimensional DNA sequencing of ultra-long DNA 
fragments, wherein DNA-sequence vs time vs imaging-reagent-space are 
simultaneously collected. Moreover, completely phased and ordered reads are 
simultaneously obtained, and the effective ”mate-pairs” for each DNA 
fragment increase combinatorially with the number of sequencers on each 
individual DNA fragment. This type of 3-D sequencing information is ideal 
for quantitating genomic structural variation and for generating de novo 
scaffolds for shorter read-length sequencing data. Many characteristics of the 
Starlight technology are known (Karrow 2010), but timing of a commercial 
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launch, target costs and other details are unknown 
(http://www.lifetechnologies.com).  
 
• Nanopore is an under development method performing ‘strand sequencing’, a 
technique where intact DNA polymers pass through a nanopore, being 
sequenced in real time as the DNA translocates the pore. A nanopore is simply 
a small hole with an internal diameter of the order of 1 nanometer. Certain 
porous transmembrane cellular proteins act as nanopores. The theory behind 
nanopore sequencing is that when a nanopore is immersed in a conducting 
fluid and a potential (voltage) is applied across it, an electric current due to 
conduction of ions through the nanopore can be observed. The amount of 
current is very sensitive to the size and shape of the nanopore. If single 
nucleotides (bases), strands of DNA or other molecules pass through or near 
the nanopore, this can create a characteristic change in the magnitude of the 
current through the nanopore. DNA could be passed through the nanopore for 
various reasons. For example, electrophoresis might attract the DNA towards 
the nanopore, and it might eventually pass through it. Alternatively, enzymes 
attached to the nanopore might guide DNA towards the nanopore. The 
potential is that a single molecule of DNA can be sequenced directly using a 
nanopore, without the need for an intervening PCR amplification step or a 
chemical labelling step or the need for optical instrumentation to identify the 
chemical label. Nanopore technologies promise no read length associated 
limitation and the possibility to sequence at 25X depth of coverage the human 
genome in minutes at a cost of 100 dollars (https://nanoporetech.com/).  
1.2.2.2 Ion Torrent PGM platform 
Ion PGM was released by Ion Torrent at the end of 2010. PGM uses semiconductor 
sequencing technology and is the first commercial sequencing machine that does not 
require fluorescence and camera scanning, resulting in higher speed, lower cost, and 
smaller instrument size. Currently, it enables 200 bp reads in 2 hours and the sample 
preparation time is less than 6 hours for 8 samples in parallel. 
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Library construction includes DNA fragmentation, enzymatic end polishing, and 
adapter ligation. Amplification of library fragments occurs by a unique approach 
known as emulsion PCR. An oil–water emulsion is created to partition small reaction 
vesicles that each ideally contains one sphere, one library molecule and all the 
reagents needed for amplification. The beads have covalently linked adapter 
complementary sequences on their surfaces to facilitate amplification on the bead. 
Although one emPCR reaction can generate billions of templated spheres, some 
aspects inherent to the emPCR method, in addition to the general biases during PCR 
amplification, prevent optimal output. In fact, due to the double Poisson distribution 
behaviour, it is impossible to achieve optimal loading of one library molecule into all 
individual vesicles. In fact 1/3 of the vesicles will have the one molecule to one 
vesicle ratio, the remaining 2/3 will be either without a molecule or have more than 
one. In the final step spheres containing amplified DNA are selected in an enrichment 
step from empty spheres and the loaded spheres are deposited into the sequencing 
chip. The Ion torrent chip consists of a flow compartment and solid state pH sensor 
micro-arrayed wells that are manufactured using processes built on standard CMOS 
technology. The sequencing reaction take place in every chip microwell which can 
contain only a single template-positive beads and DNA polymerase enzyme. In every 
sequencing step, or flow, the chip is washed over with a specific nucleotide. The 
nucleotide in the flow is incorporated by all consecutive complementary nucleotides 
‘hanging’ at the end of each template. Each incorporation releases an ion, so that the 
change in pH level indicates whether incorporation occurred and, if so, the number of 
consecutive bases incorporated (Figure 11) (Flusberg et al 2010). 
 
 
Figure 11: On the right, a schematic structure of the Ion Chip demonstrates the addition of nucleotide causing release of the 
hydrogen ion H+. This leads to changing of pH of the surrounding solution and the detection then occurs using a sensor 
underneath each well, working as a solid-state pH meter. Off-chip electronics finally digitise the voltage to digital information 
and the base calling. On the left is shown the sequencing by synthesis process based on pH sensing. When every nucleotide is 
incorporated, a hydrogen ion is released and the base is called (Mardis 2013). 
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2. PRINCIPAL AIM 
The goal of this project is to develop and validate a broad, reliable, rapid and cost-
saving genetic test for PKD patients based on NGS technology, with a sensitivity 
comparable with Sanger sequencing. 
Up to date, Sanger sequencing represent the most used method in molecular 
diagnostics, however the large size and the molecular complexity of PKD causative 
gene, i.e. GC rich regions, high allele heterogeneity and in particular the high 
homology for the first 33 exons with 6 pseudogenes of PKD1 gene make this method 
technically challenging, labor intensive and costly. 
 
This innovative test may be useful for the molecular diagnostics of ADPKD and 
ARPKD guaranteeing to reach quickly medical reports for all patients and their 
presyntomatic related, so should have great consequences on disease management and 
patient treatment. 
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3. MATERIALS AND METHODS 
3.1 Patients recruitment 
All the patients submitted to the developed NGS protocols were recruited by 
Nephrology and Medical Genetics Operative Units of the Sant’Orsola University 
Hospital in Bologna after obtaining informed consent for genetic study. 
• ADPKD cohort: 125 unrelated patients with an ADPKD clinical suspect were 
sequenced by our NGS approach with the purpose of carry out a retrospective 
and a prospective method validation. This cohort was constituted of 20 
patients, previously investigated by other specialized Italian laboratories with 
Sanger sequencing, and 105 patients with unknown mutations.  
• ARPKD cohort: 28 unrelated patients recruited were divided in two groups 
(A and B): Group A consisted of 15 unrelated probands with clinical suspect 
of ARPKD, including 2 fetuses from terminated pregnancy and 2 severely 
affected newborns who died shortly after birth; Group B counted 13 unrelated 
healthy carriers, as parents of affected ARPKD fetuses. 
5 probands (Group A) and 7 healthy carriers (Group B) had been previously 
analyzed with traditional sequencing by other specialized Italian laboratories. 
These 12 patients and the remaining 16 subjects were submitted to the NGS 
test in order to obtain a retrospective and prospective validation of the 
developed method, respectively. 
 
3.2 DNA extraction routine 
Genomic DNA was extracted from 400 µl. of peripheral blood using the semi-
automatic Maxwell® 16 instrument and the Maxwell® 16 DNA Purification kit 
(Promega Corporation, Madison, WI, USA) and were eluted in 300 µl of steril water. 
For the purpose of this study, when prompted by the machine the protocol selected 
was “Blood” and the sample type selected was “DNA”.  
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All samples were quantified using Nanodrop 3.0.0 spectrophotometer (Celbio S.P.A. 
Milano, Italia) and were normalized to 30-50 ng/µl. 
 
3.3 Next-Generation Sequencing protocol 
For the libraries constructions step, two different protocols were developed, one was 
the standard protocol based on Ion Ampliseq Technology used for the sequencing of 
PKD2 and PKHD1; the second was an alternative protocol, based on target 
preseletion using LR-PCR, for the specific amplification of PKD1. 
3.3.1 PKHD1 and PKD2 libraries construction protocol 
3.3.1.1 Assay Design 
The assay design for the mutational screening of PKD2 and PKHD1 was carried out 
by Ion AmpliSeq™ Designer (https://ampliseq.com/browse.action), a free design tool 
available online, that allow to obtain custom assay designs based on PCR target 
selection. The tool allowed us to obtain two different primer pools, for each gene, in 
order to set up ultra-high multiplex PCR for the simultaneous target amplification, i.e 
the entire coding sequence and flanking exon regions . A total of 122 amplicons for 
PKHD1 gene (61 amplicon for each pools) and 39 amplicons for PKD2 (18 in pool 1 
and 19 in pool 2) were obtained for the 99.88% and 99.9% of target coverage 
respectively.  
3.3.1.2 Libraries amplifications 
Libraries were carried out using 10ng of DNA for each pool using Ion AmpliSeqTM 
Library Kit 2.0 (Life Technologies, Carlsb8ad, CA, USA). The reaction mix and the 
termalcycler conditions are reported below (Table 3).  
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Reaction mix for sample Volume (µl) 
Ion AmpliSeqTM HiFi Master 
Mix (5X) 2 
Ion AmpliSeqTM Primer Pool 
1 (or for Pool 2) (2X) 5 
gDNA (10 ng) 1 
H2O Nuclease-free 2 
Final volume 10 
 
Temperature 
T(°C) Time Cycles 
99 °C 2′ 1 
99 °C 15′′ 19 for PKHD1/ 
21 for PKD2 60 °C 4′ 
10 °C Hold End 
 
 
Table 3: reaction mix and termalcycler conditions for libraries construction. 
3.3.1.3 Primers digestion 
Partial digestion of primers was carried out by adding 2 µL of FuPa reagent and the 
thermocycler was set to the following programme: 50°C for 10 min, 55°C for 10 min, 
60°C for 20 min and then held at 10°C for up to 1 hour.  
3.3.1.4 Adapter and barcodes ligation 
First for every barcoded adapter a final diluition of 1:4 was prepared by mixing Ion 
P1 adapters and Ion XpressTM Barcode (X), then the reaction mix reported in table 
below was added to each samples (Table 4). 
 
Reaction mix for sample Volume (µl) 
Switch solution 2 
Barcode adapter mix (1:4) 1 
DNA ligase 1 
H2O nuclease-free 1 
Final volume 6 
 
Temperature 
T(°C) Time 
22 °C 30′ 
72 °C 10′ 
10 °C Hold 
 
 
Table 4: reaction mix for barcoding stage and termalcycler conditions. 
3.3.1.5 Libraries purification 
A purification step then took place using the Agencourt® AMPure® XP reagent 
(Beckman Coulter, Brea, CA, USA) by adding 22,5 µL of the beads to each sample 
(1.8X of the original sample). The mixture was incubated for 5 minutes at room 
temperature and then placed in a magnetic rack for 2 minutes. As the required 
sequencing libraries were in the pellet, the supernatant was discarded without 
touching the beads. Two ethanol washes were performed by adding 100 µL of 70% 
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ethanol and then the pellet was left to air-dry for up to 5 minutes. Finally the sample 
was eluted using 25 µL of low Tris-EDTA pH 8.0.  
3.3.1.6 Libraries quantification and pooling 
For each library a 100-fold dilution was carried out by mixing 2 µL of the sample 
with 198 µL of nuclease-free water and three 10-fold serial dilutions were prepared of 
the E. coli DH10B Ion Control Library (~68 pM; from the Ion Library Quantitation 
Kit) at 6.8 pM, 0.68 pM, and 0.068 pM. Each standard, negative control and the 
samples were analysed in duplicate using Ion Library Quantitation Kit (Life 
Technologies, Carlsbad, CA, USA). Reaction mix and PCR conditions are shown in 
tables below (Table 5). 
Reaction mix for sample Volume (µl) 
2X Ion TaqMan® Master Mix 5 
20X Ion TaqMan® Assay 0.5 
Library (1:100) or standards DH10B  4,5 
Final volume 10 
 
Temperature Time Cycles 
50 °C 2′ Hold 
95 °C 20′′ Hold 
95 °C 1′′ 40 
60 °C 20′′   
10 °C End  Hold  
 
 
Table 5: reaction mix for quantification stage and termalcycler conditions. 
Following quantitation the sequencing libraries were pooled together to 9 pM as to 
ensure they were suitable for template preparation. 
3.3.2 PKD1 libraries construction protocol 
3.3.2.1 Assay design  
In order to obtain the specific and selective PKD1 genuine gene amplifications, rare 
mismatch sequencing between PKD1 and pseudogenes had been used to develop 
PKD1 locus-specific amplicons. Primer set design was carried out using two different 
tools available online: Primer3 (http://primer3.ut.ee/) was used for primers design, 
PrimerBlast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to checked 
the target specificity and Operon Oligo Analyzer (http://eu.idtdna.com/calc/analyzer) 
was finally used to exclude the self complementarity between primers. The primers 
set designed is reported in Table 6. 
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Exons 
covered Forward primer (5’-3’) Reverse primer (5’-3’) Kb 
1 CGCAGCCTTACCATCCACCT TCATCGCCCCTTCCTAAGCA 2,3 
2-12 CCAGCTCTCTGTCTACTCACCTCCGCATC CCACGGTTACGTTGTAGTTCACGGTGACG 8,7 
13-21 TGGAGGGAGGGACGCCAATC ACACAGGACAGAACGGCTGAGGCTA 7,9 
22-33 CCGCCTCTCCTCTCTCCCCTCCT ACCTGCTGGATCAGGTCTTC 7,9 
34-41 AGGAGGGGGCTCTGAAGCTCACCCTT AGAGGGTGCGGGTCAGTAGG 5,7 
42-46 CCAGGAGCCCACCCTCACTC CCATTCTGCCTGGCCCTC 2,7 
 
 
Table 6: Oligonucleotide primers for long-range specific templates from exons 1 to 46 of the PKD1 gene  
LR-PCRs were performed using two different kits: GoTaq® Long PCR Master Mix, 
(Promega, Madison, WI, USA) and PrimeSTAR GXL DNA Polymerase (Takara Bio 
USA, Inc). Reaction mixes and termalcycler conditions are reported in the table 
below. 
 LR-PCR Exon 1 (TARGET: 2278bp) 
 GoTaq® Long PCR Master Mix (Promega, 
Madison, WI, USA) 
Reaction mix µl 
H2O 6.5 
GC rich Buffer (5X) 10 
Master Mix (2X) 25 
Primer forward 1F (20 pmol/µl) 1.25 
Primer reverse 1R (20 pmol/µl) 1.25 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
95 2′ 1 
95 30′′ 	64 30′′ 35 
72 3′ 		
72 10′ 1 
10 HOLD END 
 
LR-PCR Exons 2-12 (TARGET: 8727bp) 
PrimeSTAR GXL DNA Polymerase (Takara) 
Reaction mix µl 
H2O 25 
Buffer (5X) 10 
dNTPS mixture (2.5 mM each) 5 
Primer Forward 2-12F (20 pmol/µl) 1.5 
Primer reverse 2-12R (20 pmol/µl) 1.5 
Taq (1.25 U/µl) 1 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
98 10′′ 35 68 8'30" 
10 ∞ END 
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LR-PCR Esons 13-21 (TARGET: 78927bp) 
GoTaq® Long PCR Master Mix (Promega, 
Madison, WI, USA)	
Reaction mix µl 
H2O 6.5 
GC rich buffer (5X) 10 
Master Mix (2X) 25 
Primer forward 13-21F (20 pmol/µl) 1.25 
Primer reverse 13-21R (20 pmol/µl) 1.25 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
95 2' 1 
95 30" 	66 30" 35 
72 8:30" 		
72 10' 1 
10 ∞ HOLD 
 
LR-PCR Esons 22-33 (TARGET: 78927bp) 
GoTaq® Long PCR Master Mix (Promega, 
Madison, WI, USA)	
Reaction mix µl	
H2O 16,5 
Master Mix (2X) 25 
Primer forward 22-33F (20 pmol/µl) 1.25 
Primer reverse 22-33R (20 pmol/µl) 1.25 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
95 2' 1 
95 30" 	72(-0,5) 30" 10 
73 7:30' 		
95 30" 	64 30" 25 
73 7:30' 		
73 5' 1 
10 ∞ END 
 
 
LR-PCR Esons 34-41 (TARGET: 5700bp) 
GoTaq® Long PCR Master Mix (Promega, 
Madison, WI, USA)	
Reaction mix µl	
H2O 16.5 
Master Mix (2X) 25 
Primer forward 34-41F (20 pmol/µl) 1.25 
Primer reverse 34-41R (20 pmol/µl) 1.25 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
95 2' 1 
95 30" 
35 70 6' 
72 10' 1 
10 ∞ END 
 
LR-PCR Esons 42-46 (TARGET: 2763bp) 
GoTaq® Long PCR Master Mix (Promega, 
Madison, WI, USA)	
Reaction mix µl	
H2O 6.5 
GC rich buffer (5X) 10 
Master Mix (2X) 25 
Primer forward 42-46F (20 pmol/µl) 1.25 
Primer reverse 42-46R (20 pmol/µl) 1.25 
gDNA (35-50ng) 6 
Final volume 50 
 
Temperature 
(°C) Time Cycles 
94 2' 1 
94 30" 35 62 30" 
72 3' 1 72 10' 
10 ∞ END 
 
 
Table 7: all reaction mix and termalcycler conditions for LR-PCR 
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3.3.2.2 LR-PCR purification, quantification and pooling 
All LR-PCR products were then purified by filtrations over Montage PCR 96 clean up 
plates (millipore Corp., Billerica, MA, USA) and quantified using Qubit dsDNA BR 
Assay Kit and Qubit® Fluorometer 2.0 instrument (Invitrogen, Carlsbad, CA, USA). 
Finally, all LR-PCR, for each patient, were pooled together in equimolar manner 
(50pM each) in a final volume of 100 µl. 
3.3.2.3 Sonication and end repair 
In order to obtain uniform genomic libraries constituted of 200bp amplification 
fragments, all the pool were sonicated using Bioruptor® Pico (Diagenode) for 13 
cycles at full amplitude 30 seconds ON/ 30 seconds OFF. The tubes containing the 
DNA were held in an ice bath during sonication. The sticky-end generated by 
fragmentation step were then converted in blunt-end using Ion Plus Fragment Library 
Kit (Life Technologies, Carlsbad, CA, USA). The equimolar amplicons of 100 ng 
were mixed with 20 µl of 5X end repair buffer and 1 µl of end repair enzyme in a 1.5 
ml low binding tube, then the tube was incubated at room temperature for 20 minutes. 
The fragmented DNA was purified by Agencourt® AMPure® XP reagent by adding 
1.8X of the total volume of the fragmented sample as shown in section 3.3.1.5. 
3.3.2.4 Barcode and adapters ligation, nick repair and purification  
The purified DNA fragments were then transferred ligated to adaptors and nick-
repaired following the reaction mix and the termalcycler conditions as indicated in 
table 8. 
Reaction mix Volume (µl) 
DNA ~25 
Ligase Buffer (10X) 25 
Ion P1 Adapter 2 
Ion XpressTM Barcode X[1] 2 
dNTP Mixture 2 
Nuclease-free Water 49 
DNA Ligase 2 
Nick Repair Polymerase 8 
Final volume 100 
 
Temperature 
(°C) Time Cycles 
25 °C 15′ Hold 
72 °C 5′ Hold 
4 °C up to 1h Hold 
 
 
Table 8: reaction mix and termalcycler conditions for barcode-adapters ligations and nick repair 
[1] refers to the barcode number. 
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Following the run on the thermocycler, the ligation reactions were purified with 1.4X 
of Agentcourt® AMPure® reagent for 200base-reads sequencing as discussed above in 
section 3.3.1.5. 
3.3.2.5 Size selection of DNA libraries and quantifications 
In order to select only ligated library fragments of ~250 bp in size (~200bp of 
fragment library + 40bp adapters + 10 bp barcode) the size selection was performed 
using E-GelTM iBaseTM unit and E-GelTM Safe ImagerTM transilluminator instruments 
and E-GelTM SizeSelectTM 2% Agarose precasted Gel (Invitrogen, Carlsbad, CA, 
USA). 
10 µl of 50bp DNA ladder (1 µg/µL, diluited 1:40) and 20 µl of ligated libraries were 
loaded to the loading well on the top of the E-GelTM SizeSelectTM 2% Agarose so all 
the recovery well were filled with 20 µl of Nuclease-free water. When prompt by the 
machine “SizeSelectedTM 2%” program was selected and the run was monitored until 
the 370bp sized ladder band (350bp) was in the reference line then the run was 
stopped and the solution within recovery wells (at the bottom of the precasted gel) 
was collected in 0,2 ml tubes. 
Prior to preparing the sequencing template, the size-selected sequencing libraries were 
quantified using the Ion Library Quantitation Kit (Life Technologies, Carlsbad, CA, 
USA) as described in section 3.3.1.6 and the different libraries were pooled together 
at final concentration of 9pM. 
3.3.3 Sequencing template preparation: Emulsion PCR 
Sequencing template preparation was performed using the Ion PGM Hi-Q OT2 Kit 
and Ion OneTouchTM 2.0 instrument (Life Technologies, Carlsbad, CA, USA). 
Reaction mix was prepared in the 2 ml tube containing 800 µl of Ion PGMTM Hi-QTM 
Reagent Mix as reported in the table 9. 
 
Reaction mix Volume (µl)	
Nuclease-free water 25 
Ion PGMTM HI-QTM Enzyme mix 50 
Diluited library (9pM) 25 
Ion PGMTM HI-Q ISPs 100 
 
 
 
Table 9: reaction mix used for emulsion PCR 
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The amplification mixture was added to the sample port of the Ion PGMTM OneTouch 
Plus Reaction Filter and then 1700 µl of Ion OneTouchTM Reaction Oil was added to 
the filter sample port, as well. The filled Ion PGMTM OneTouch Plus Reaction Filter 
was inverted and installed into the three holes on the top stage of Ion OneTouchTM 2.0 
instrument and two recovery tubes with 150 µl of Ion OnetouchTM Breaking Solution 
were inserted in the instrument centrifuge. Finally, the clonal amplification was 
performed by running the emulsion mixture setting the “Ion PGM Hi-Q OT2 200” 
protocol.  
At the end of the run and final spin, all but 100 µl of the Ion PGMTM OT2 Recovery 
Solution (surnatant) was removed from each recovery tubes, then 500 µl of Ion One 
TouchTM Wash Solution was added in each tube and the ISPs (Pellet) were mixed by 
pipetting and were combined into a new labeled 1.5 ml eppendorf LoBindTM Tube. 
The tube was centrifuged for 2.5 minutes at 15,500 x g and all but 100 µl of the 
surnatant was discarded. 
The quality of the unenriched template was assessed using Qubit® 2.0 Fluorometer. 
3.3.4 Template-positive ISPs enrichment 
The template-positive ISPs entichment was carried out using Ion OneTouchTM ES 
instrument and Ion PGMTM Enrichment Beads Kit (Life Technologies, Carlsbad, CA, 
USA). 
Dynabeads® MyOneTM Streptavidin C1 Beads were created by mixing the tube for 
30 seconds to resuspende the beads, immediately 13 µl of Dynabeads® MyOneTM 
Streptavidin C1 Beads was transferred into a 1,5mL Eppendorf LoBind tube and 
placed on a magnetic rack for 2 minutes. The surnatant was removed carefully 
without disturbing the pellet, then 130 µl of MyOneTM Beads Wash Solution was 
added and beads were mixed by pipetting. 
An opened 0.2 mL tube containing 10 µl of Neutralization Solution was insert into the 
hole at the base of instrument and the 8-well strip (Figure 12) was filled as reported 
above. 
1. 100 µl of entire template-positive ISP sample; 
2. 130 µl of Dynabeads® MyOneTM Streptavidin C1 Beads resuspended in 
MyOneTM Beads Wash Solution: 
3. 300 µl of Ion OneTouchTM Wash Solution; 
4. 300 µl of Ion OneTouchTM Wash Solution; 
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5. 300 µl of Ion OneTouchTM Wash Solution; 
6. Empty; 
7. 300 µl of freshly prepared Melt-Off Solution (125mM NaOH and 0.1% 
TweenTM 20 detergent); 
8. Empty. 
 
Figure 12: the 8-well strip using for template enrichment 
 
 
3.3.5 Ion Torrent PGMTM sequencing  
Ion PGMTM sequencing platform was cleaned and initialized following the 
manufacture’s instructions. 
The template-positive ISPs enriched sample was centrifuged for 2.5 minute at 15,500 
x g, then all but 15 µl of surnatant was carefully discarded without disturbing the 
pellet and 3 µl of sequencing primer was added, finally the sample was incubated in 
termalcycler following the condition reported in table 10. 
 
Temperature 
(°C) Time Cycles 
95 °C 2′ 1 
37 °C 2′ 1 
 
 
Table 10: termalcycler conditions for annealing primer. 
 
Following the incubation step, 3 µl of Ion PGMTM Hi-Q sequencing polymerase was 
added and the sample was incubated at room temperature for 5 minutes. 
The Ion 318TM v2 Chip was assessed for sequencing. First of all, the chip was tilted to 
45 degrees to discard the liquid inside and a pipette tip was firmly inserted into the 
loading port, then it was placed upside-down in the centrifuge adapter bucket and the 
bucket was transferred to the MiniFuge with the chip tab pointing in and it was 
centrifuged for 5 seconds. After liquid removal, the chip was loaded slowing into 
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loading port with 30 µl of sequencing reaction. After three different step of 
centrifuged of 30 seconds, alternating the tab chip positions (in and out for each 
cycle) the reaction sequencing was mixed by tilting the chip to 45 degrees by 
pipetting the sample in and out of the chip. 
At the end of centrifuge cycles, all the liquid was removed from the loading port and 
the chip was finally positioned in the Ion PGMTM sequencer. 
3.3.6 NGS data analysis  
Ion PGMTM Sequencer transferred the row sequencing data to the Torrent Server, that 
converted this one to base calls and the Torrent SuiteTM generated a summary 
sequencing report and different files for analysis including Fastq files, Binary 
Alignment Map (BAM) in conjunction with Binary Alignment Index (BAI) and 
Variant Call Format (VCF) files. The sequencing samples were aligned to two 
reference genome in order to obtain Variant caller Files: PKD2 and PKHD1 reads 
were aligned to human genome (hg19), whereas PKD1 reads were aligned against an 
artificial reference genome based on chromosome 16 of hg19, where all the 
nucleotides outside the PKD1 locus were masked and replaced with “Ns”.  
The BAM/BAI files, generated following the alignment, were visualized using 
Integrative Genome Viewer (IGV) Software. IGV was used to assess the depth of 
coverage of the sequencing reads, zygosity, quality of the sequencing reads and the 
mapping quality.  
All the VCF files were uploaded into Ion Reporter software 
(https://ionreporter.thermofisher.com/ir/) selecting the Annotation Variant workflow 
in order to associated to each variant the nucleotide change in mRNA transcript, the 
aminoacidic change, the exons or IVS and the function. Moreover the Ion Reporter 
can readily access several prediction programs used to evaluating the pathogenic 
potential of missense change, providing important information about the 
pathogenicity of the variants analyzed (see section 3.3.6.1). 
3.3.6.1 Variant filtering strategy 
All the variant found were classified following the The American College of Medical 
Genetics and Genomics 2015 (Richards et al 2015) in 5 principal categories: 
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1. Pathogenic: all the Loss of Function (LOF) mutations as nonsense, frameshift, 
indel non-frameshift, canonical splicing variants, and the SNP occurring into 
the ATG starting codon; 
2. Likely Pathogenic: all the missense described as pathogenic variants listed in 
Autosomal Dominant Polycystyc Kidney Disease Mutation Database (PKDB: 
http://pkdb.mayo.edu) for ADPKD patients, Humgene 
(http://www.humgen.rwth-aachen.de) for ARPKD patients and in the Leiden 
Open Variations Database (LOVD3.0: http://www.lovd.nl/3.0/home), and the 
novel missense variants with a MAF < 0,002 (http://exac.broadinstitute.org), 
predicted as pathogenic by bioinformatic tools as Polyphen 2.0 
(http://genetics.bwh.harvard.edu/pph2/), SIFT BLink 
(http://sift.jcvi.org/www/SIFT_BLink_submit.html); 
3. Variant of Uncertain Significance (VUS) all novel missense rare variants with 
discordant prediction results. 
4. Likely Benign: all frequent missense variants and rare synonims and intronic 
(near the canonical splicing site) variants predicted as not affects function by 
Human Splicing finder (http://www.umd.be/HSF3/); 
5. Benign: all the deep intronic variants and frequent synonyms variant in non-
conserved sequence domains.  
 
3.4 Validation of the NGS data by Sanger sequencing 
Sanger sequencing was performed in order to validate all the variants classified as 
pathogenic, likely pathogenic and VUS. 
For PKD1 validation variants, LR-PCR products were obtained starting to a new 
DNA extraction as described in section 3.3.2.1, then the obtained amplicons were 
purified as described in section 3.3.2.2 and the purified template was used to perform 
nested PCR by specific primers designed to amplified the region containing the 
variant. 
The nested PCR were purified again following the procedure described in section 
3.3.2.2 and then sequenced by Sanger technique using ABI Prism 3730 DNA 
Analyzer (Applied Biosystem, Foster City, CA, USA). The reaction mix and the 
termalcycler conditions are reported in table 11. 
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Reaction mix Volume (µl) 
Nuclease-free water 4 
Big-DyeTM Buffer (5X) 2 
Big-DyeTM Terminator 3.1 1 
Primers (3,2 pmol/µl) 1 
Purified Template (25 fmol) 2 
Final volume 10 
 
Temperature 
(°C) Time Cycles 
96 °C 30′′ 1 
96 °C 10′ 25 60 °C 3′ 
10 °C 4 Hold 
 
 
Table 11: reaction mix and termalcycler conditions for Sanger sequencing reaction. 
 
For PKHD1 and PKD2 variant validations the LR-PCR step was avoided and the 
specific sequences including the variants were directly amplified and sequenced 
following the instruction reported above. 
 
3.5 Multiplex Ligation-dependent Probe Amplification: MLPA 
In order to identified large genomic rearrangement and copy number variations 
(CNVs), all the ADPKD patients resulting wild-type to NGS test were submitted to 
MLPA using commercial kit containing specific probe for PKD1 and PKD2 gene 
(Salsa® MLPA® P351PKD1 probe mix and Salsa® MLPA® P352 PKD1-PKD2 
probe mix (MRC Holland, Amsterdam, NL)). 
The protocols consisted of three different steps: 
• DNA denaturation and probe ibridization: genomic DNA, freshly 
extracted, was normalized on a concentration of 20ng/µl then was incubated at 
98°C for 10 minutes. In the meanwhile, a probe ligation mix was prepared and 
added to each samples and the samples were incubated in termalcycler as 
reported in table 12. 
 
Ibridization ligation mix Volume (µl) 
Salsa® MLPA® P351PKD1 probe mix or 
Salsa® MLPA® P352 PKD1-PKD2 probe mix 1.5 
Salsa® MLPA® Buffer 1.5 
Final volume 3 
 
Temperature 
(°C) Time Cycles 
95 1’ 1 
60 16-20h HOLD 
 
 
Table 12: ibridization reaction mix and termalcyler conditions 
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• Probe Ligation: the following day all the probes were ligated as reported in 
table 13. 
Ligation mix Volume (µl) 
Nuclease-free H2O 25 
Ligase Buffer A 3 
Ligase Buffer B 3 
Salsa Ligase-65 1 
Final volume 32 
 
Temperature 
(°C) Time Cycles 
54 15’ 1 
98 5’ 1 
20 END HOLD 
 
 
Table 13: ligation mix and termalcycler conditions. 
 
• Probe Amplification: all the ligated probes were amplified following the 
reaction mix and termalcycler conditions reported in table 14. 
Amplification mix Volume (µl) 
Nuclease-free H2O 7.5 
Salsa PCR primer 2 
Salsa Polymerase 0.5 
Final volume 10 
 
Temperature 
(°C) Time Cycles 
95 30’’ 
34 
60 30’’ 
72 1’ 
72 20’ 
10 END HOLD 
 
 
Table 14: amplification probe mix and termalcycler conditions. 
 
At the end of the probe amplification 1 µl was used for capillary electrophoresis on 
ABI Prism 3730 DNA Analyzer (Applied Biosystem , Foster City, CA, USA) and the 
electopherograms were analyzed by Coffalyzer software (MRC Holland, Amsterdam, 
NL). 
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4. RESULTS AND DISCUSSIONS 
4.1 Critical assay analysis 
The Next-Generation Sequencing technology, characterized by high throughput and 
convenient benchtop workflows, was used to develop a rapid and cost-effective 
molecular diagnostic method for polycystic kidney disease. 
The NGS platform used in this work was the Ion Torrent Personal Genome 
MachineTM (Life Technologies, Carlsbad, CA, USA), a highly suitable instrument for 
targeted-resequencing assay for DNA, RNA and small genomes.  
For the purpose of this study two different protocols were developed, one was based 
on Ion AmpliseqTM technology for the target-resequencing of PKD2 and PKHD1 
genes, and one was based on a target pre-selection strategy for the molecular 
screening of PKD1. 
Two different custom panels were obtained for PKD2 and PKHD1 using Ion 
Ampliseq DesignerTM. The overlapping amplicons generated by the software, divided 
in two pools for each gene, allowed us to achieve ultra-high multiplexing-PCR for the 
complete coverage of the entire coding sequences, i.e. exons and their flanking 
regions.  
The custom PKD2 and PKHD1 panels, respectively formed by 39 and 122 
overlapping amplicons, provided for the simultaneous amplification of the entire 
target regions for each genes in only two multiplex reactions with 99.9% and 99.88% 
target coverage respectively (Figure 13). 
All the missed regions, 2 bp in exon 2 of PKD2 and 15bp in exon 65 of PKHD1, were 
sequenced by Sanger sequencing. 
 
A 
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The library barcoding allowed the simultaneous sequencing of more patients per run. 
Despite the considerable dimension of PKHD1 target region an average coverage of  
≥ 300X was obtained for the simultaneous sequencing of 12 patients, whereas an 
average coverage of over 400X was obtained submitting 24 patients in a single run for 
PKD2 screening  
Although the Ampliseq-based protocol proved to be effective and suitable for the 
PKD2 and PKHD1 sequencing, the Ampliseq technology was not reliable for PKD1 
specific sequencing. The majority of the overlapping amplicons generated by 
Ampliseq DesignerTM caused the unspecific co-amplification of homologus regions, 
leading to a substantial loss of sensitivity and specificity, especially in the 1-33 exons 
encompassing region.  
To improve PKD1 sequencing assay and to eliminate the unspecific pseudogene 
amplification, a LR-PCR-based strategy was developed (Figure 14A). By using 
computational analysis, a set of six oligonucleotide primer pairs was designed that 
matched the single-copy gene and rare sequence differences between PKD1 and the 
pseudogenes. The unique LR-PCR oligonucleotides were carefully designed to cover 
approximately 35,1 kb of genomic sequence, including entire coding sequence, exon-
intron boundaries and most of the 5’- and 3’-untranslated regions. 
The agarose gel electrophoresis with ethidium bromide staining of the LR-PCR 
products demonstrated that the fragment dimensions corresponded exactly to the 
expected base pair for PKD1 (Figure 14A-C). 
 
Figure 13: the output of Ion Ampliseq Designer for PKD2 (A) and PKHD1 (B) were reported in figure. The first line (blue) 
represents the gene reference sequence (hg19); full squares and line indicate exons and intronic regions respectively. The second 
line (light blue) reports submitted regions and the third (green) and fourth (red) lines represent respectively the covered target 
and the missed regions (indicated by the red arrow). 
B 
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Figure 14: visualization of PKD1 NGS workflow. PKD1 was amplified as 6 locus-specific LR-PCR products. A: Map of the 
PKD1 gene showing the position of the 6 primer pairs used for LR-PCR amplification of the coding region. B: LR-PCR products 
from each patients were pooled together in equimolar ratio and sonicated to obtained 200bp genomic library than were assessed 
for quality using Agilent Bioanalizer Instrument. C: Amplification quality was verified using agarose gel electrophoresis.  
 
All LR-PCR products were purified, quantified and pooled in equimolar manner in 
order to obtain a single pool for each patient that underwent sonication with the 
purpose of creating a 200 bp fragment genomic library (Figure 14B). 
To evaluate the NGS workflow, individually barcoded library 16 patients were 
submitted to this alternative protocol and the reads were visualized by Integrative 
Genome Browser software (Figure 15) in order to estimate the target coverage and the 
reads quality. As it is shown in the figures, despite 100% of target coverage beeing 
obtained (Figure 15A), a low mapping quality score characterized some reads (Figure 
15B), in particular, all the reads which sharing high homology with pseudogenes 
regions. 
It occurred because, using the assembly hg19 as reference genome, the reads sharing 
high homology with pseudogenes misaligned in pseudogenes loci and were 
recognized as “errors” by the software. To solve this problem, we created an artificial 
genome, based on chromosome 16 annotated in hg19, where all the nucleotides 
outside PKD1 locus were masked and replaced with “Ns”. Thanks to this artificial 
genome, a high mapping score was obtained for all the reads and the test sensitivity 
and specificity improved (Figure 15C). Moreover this procedure allowed maintaining 
the genomic coordinates of the variants and enabling subsequent variant annotations 
using standard NGS analysis software.  
Ex	1 
(2,3kb) Ex	34-41 
(5,7kb) 
Ex	42-46 
(2,7kb) 
Ex	13-21 
(7,9kb) 
Ex	2-12 
(8,7kb) Ex	22-33 (7,9kb) 
PKD1 
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A 
C
B
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Figure 15: visualization of PKD1 mapped reads using assembly hg19 (A and B) and the Chr16 modified genome (C) as 
reference sequences. Forward and reverse reads are represented in pink and blue respectively; all reads characterized by low 
mapping quality score are indicated in white. A): Using hg19 as reference genome several reads had low mapping quality score 
producing a missed variant calling. B): a detail in 2-8 exons encompassing regions is shown and quality score mapping is 
reported for “good” (blue arrow) and “bad” (red arrow) reads. C): the use of artificial Chr16 modified genome allows to 
obtaining high mapping quality score for all reads increasing sensibility and specificity of PKD1 screening test. 
 
A
B
A 
B
b
C
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4.2 NGS protocols: retrospective validation 
To determine the accuracy of our NGS protocols, we collected and sequenced DNA 
from 20 ADPKD and 12 ARPKD previously characterized patients. All these patients 
had been sequenced by Sanger by other specialized Italian laboratories and were used 
to conduct a blind analysis in order to compare the two techniques.  
• ADPKD 
In a limited 20-sample validation cohort which included 19 patients with known 
mutations in PKD1 and one in PKD2, the NGS protocols showed 100% analytic 
sensitivity in detecting all the pathogenic variations (Table 15).  
 
Table 15: schematic representation of retrospective validation phase 
 
Previously	characterized	mutation	
(SANGER)	
Confirmed	
mutations	
Gene	 c.DNA	 Protein	 EX/IVS	
n°	of	
unrelaed	
patients	
NGS	
PROTOCOL	
PKD1	 c.803dup	 p.Phe269Leufs*102	 5	 1	 ✓ 
PKD1	 c.1295C>T	 p.Ala432Val	 6	 1	 ✓ 
PKD1	 c.2098-2_2109del	 p.(?)	 IVS10	 1	 ✓ 
PKD1	 c.2494dupC	 p.Arg832Profs*40	 11	 1	 ✓ 
PKD1	 c.2695C>G	 p.Leu899Val	 11	 1	 ✓ 
PKD1	 c.2986-2_2987del	 p.(?)	 IVS12/EX13	 1	 ✓ 
PKD1	 c.4429del	 p.Leu1479Trpfs*55	 15	 1	 ✓ 
PKD1	 c.4494C>G	 p.Tyr1498*	 15	 1	 ✓ 
PKD1	 c.6040C>T	 p.Gln2014*	 15	 1	 ✓ 
PKD1	 c.7663G>A	 p.Val2555Met	 19	 1	 ✓ 
PKD1	 c.8000C>A	 p.Ala2667Glu	 21	 1	 ✓ 
PKD1	 c.8311G>A	 p.Glu2771Lys	 23	 2	 ✓ 
PKD1	 c.8428G>T	 p.Glu2810*	 23	 1	 ✓ 
PKD1	 c.8860G>T	 p.Glu2954*	 24	 1	 ✓ 
PKD1	 c.9404	C>T	 p.Thr3135Met	 27	 1	 ✓ 
PKD1	 c.9713-2A>G	 c.9713-2A>G	 IVS28	 1	 ✓ 
PKD1	 c.11257_11269+3del	 p.(?)	 EX39/IVS39	 1	 ✓ 
PKD1	 c.11819dup	 p.Leu3941Alafs*20	 43	 1	 ✓ 
PKD2	 c.540_555dup	 p.Arg186Glyfs*32	 1	 1	 ✓ 
 
 
Table 15: Are listed all the previously identified mutations with traditional sequencing method and the NGS confirmation. For 
each mutation are reported: the gene, the nucleotide change in mRNA transcript (PKD1: NM_001009944.2 and PKD2: 
NM_000297.3), the aminoacidic change, the exons or IVS (intronic variant sequence number), and the number of times in which 
the mutations were found in unrelated patients. ✓ indicated the confirmed mutations with our NGS protocol. 
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 The data shown in table 15 demonstrates that both ampliseq-based and the LR-PCR-
based NGS protocols were specific and accurate for the correct screening of PKD1 
and PKD2 gene. Moreover, the identification of the frameshift c.540_555dup, p. 
Arg186Glyfs*32 in two unrelated patients demonstrates the test robustness.  
• ARPKD 
To test the efficacy of PKHD1 NGS Ampliseq-based protocol, a limited cohort of 12 
previously characterized patients was submitted to our assay. 
The cohort included 5 probands with an ARPKD clinical phenotype of and 7 
obligated heterozygotes (healthy carriers) for a PKHD1 pathogenic variant as parents 
of an affected child. Three of these healthy carriers (9, 11, 12) had received a 
previously negative molecular diagnosis in PKHD1 and in two probands (1, 2) only 
one pathogenic variant had been found.  
 
Table 16: schematic representation of retrospective validation phase 
 
n.	of	
unrelated	
Identified	mutation	with	NGS	protocol	 Previously	identified	mutation	(SANGER)	
ex	 cDNA	 Protein	 ex	 cDNA	 Protein	
1	
36	 c.5830G>A	 p.Asp1944Asn	 36	 c.5830G>A	 p.Asp1944Asn	
52	 c.8206T>G	 p.Trp2736Gly	 -	 -	 -	
2	
32	 c.4870C>T	 p.Arg1624Trp	 32	 c.4870C>T	 p.Arg1624Trp	
61	 c.10444C>T	 p.Arg3482Cys	 -	 -	 -	
3	
32	 c.4292G>A	 p.Cys1431Tyr	 32	 c.4292G>A	 p.Cys1431Tyr	
36	 c.5895dup	 p.Leu1966Thrfs*4	 36	 c.5895dup	 p.Leu1966Thrfs*4	
30	 c.3407A>G	 p.Tyr1136Cys	 -	 -	 -	
4	
33	 c.5336A>G	 p.Asn1779Ser	 33	 c.5336A>G	 p.Asn1779Ser	
54	 c.8470C>T	 p.Gln2824*	 54	 c.8470C>T	 p.Gln2824*	
5	
32	 c.4417C>T	 p.Gln1473*	 32	 c.4417C>T	 p.Gln1473*	
32	 c.5068T>C	 p.Ser1690Pro	 32	 c.5068T>C	 p.Ser1690Pro	
6	 15	 c.1197delC	 p.Leu400Cysfs*13	 15	 c.1197delC	 p.Leu400Cysfs*13	
7	 3	 c.107C>T	 p.Thr36Met	 3	 c.107C>T	 p.Thr36Met	
8	
55	 c.8581A>G	 p.Ser2861Gly	 55	 c.8581A>G	 p.Ser2861Gly	
61	 c.10444C>T	 p.Arg3482Cys	 -	 -	 -	
9	 52	 c.8206T>G	 p.Trp2736Gly	 -	 -	 -	
10	 2	 c.1A>G	 p.Met1Val	 2	 c.1A>G	 p.Met1Val	
11	 55	 c.8606C>A	 p.Thr2869Lys	 -	 -	 -	
12	 -	 -	 -	 -	 -	 -	
 
 
Table 16: schematic representation of the retrospective validation phase. All the identified mutations with the NGS protocol and 
the previously diagnosed mutations with conventional sequencing are listed. For each unrelated patient the mutations, the 
nucleotide change in mRNA transcript (PKHD1: NM_138694), the aminoacidic change, the exons or IVS (intronic variant 
sequence number) are reported. The mutations written in bold character represents the additional variant not previously 
discovered with traditional method. 
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As reported in table 16, the NGS protocol correctly identified all the known 
mutations. Moreover, it allowed the individuation of additional pathogenic variants in 
3 probands (1, 2, 3) consenting the complete molecular diagnosis. The c.8206T>G, 
p.Trp2736Gly (ExAc MAF=0.00001) and c.10444C>T, p.Arg3482Cys (ExAc 
MAF=0.00007) variants found respectively in probands 1 and 2 were rare variants 
described as being associated to the ARPKD phenotype (Bergmann et al 2004; Sharp 
et al 2005) and were classified as pathogenic mutations in Humgen and LOVD. The 
c.10444C>T, p.Arg3482Cys was also found to be an additional mutation in the 
healthy carrier 8 in association with the previously diagnosed variant c.8581A>G, 
p.Ser2861Gly, a novel variant, predicted as benign by the pathogenicity prediction 
tools. In this particular case, the molecular diagnosis by the NGS method was found 
to be more exhaustive, providing additional information on the genetic carrier status 
that can be advantageous for a future genetic counseling. Unfortunately we can’t 
establish if these two variant were in cis or trans because we were not able to enroll 
family members.	
Moreover, the c.3407A>G p.Tyr1136Cys, identified as additional variant in proband 
3, that had not been found by traditional sequencing method was reported in literature 
as a pathogenic mutation (Loosekoot et al 2005). 
In healthy carriers 9 and 11, which were considered wild type for PKHD1 mutations 
by the other laboratory, the NGS protocol detected the c.8206T>G, p.Trp2736Gly and 
c.8606C>A, p.Thr2769Lys respectively. The first one was the same identified in 
proband 1, whereas the second one was a rare variant (ExAC MAF=0.009332)	 in a 
non-conservative aminoacidic change but was found in literature in several ARPKD 
pedigrees (Rossetti et al 2003), therefore we considered this variant to be as uncertain 
significance (VUS). 
The healthy carrier 12 come back as a wild type for mutation in PKHD1 in both 
screening tests. The investigation of large rearrangement, in this case, is 
recommended.  
In conclusion, the NGS method correctly identified all the 12 molecular defects 
known to be present in the previously characterized samples, showing a sensitivity of 
100%. Moreover, it allowed the identification of 4 additional missense variants 
previously undetected, which were confirmed by Sanger sequencing. 
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4.3 Pathogenic variants identified by NGS tests. 
4.3.1 Molecular screening of PKD1 and PKD2 
125 patients, 20 of which with known mutations, were analyzed in this work. All 
patients were previously sequenced with NGS protocol in order to detect molecular 
defects in PKD1 and PKD2 genes; for all the wild type cases, large genetic 
rearrangements were investigated with MLPA. 
In table 17 and in figure 16 the type and the frequency of pathogenic variants, and the 
novel numbers for each type, found in PKD1 and PKD2 are reported. 
All the identified variants were confirmed by Sanger sequencing to exclude false 
positives.  
 
Table 17: all identified mutations in PKD1 and PKD2 with NGS method. 
 
TYPE	
PKD1	 PKD2	
TOTAL	 NOVEL	 TOTAL	 NOVEL	
LARGE	DELETION		 4(3.77%)	 4(100%)	 1(9.09%)	 1(100%)	
FRAMESHIFT	 23(21.70%)	 18(78.26%)	 2(18.18%)	 2(100%)	
INDEL	NON	FRAMESHIFT	 2(1.89%)	 1(50%)	 0	(0%)	 0(0%)	
NONSENSE	 26(24.53%)	 10(38.46%)	 2(18.18%)	 0(0%)	
SPLICING	 5(4.72%)	 5(100%)	 2(18.18%)	 0(0%)	
MISSENSE	 46(43.40%)	 23(50,00%)	 4(36.36%)	 2(50%)	
TOTALE	 106	 61	(57.54%)	 11	 5	(45.45%)	
 
 
Table 17: all mutations found, in this study, in PKD1 and PKD2 sorted by type. The total variant type percentage is calculated 
by dividing the number of each variant type by the total variants, while the percentage for each type of novel is calculated to each 
variant type. 
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Figure 16: The pie chart (A) reports all the mutations found in PKD1 on 99 ADPKD patients on the left, and the novel variants 
identified, on the right; (B) reports all the mutations found in PKD2 on 14 ADPKD patients on the left, and the novel variants 
identified, on the right. 
 
Our investigation allowed us to identify molecular defects in 90.4% (n=113) of the 
patients, 87.6% (n=99) presented mutations in PKD1 while 12.4% (n=14) in PKD2.  
In total 67 loss of function (LOF) mutations were detected, that we considered 
pathogenic. In particular, 28 were nonsense (26 (24.53%) in PKD1 vs 2 (18.18%) in 
PKD2), 25 were frameshift (23 (21.70%) in PKD1 vs 2 (18.18%) in PKD2), 7 were 
variants in a canonical slicing site (5(4.72%) in PKD1 vs 2 (18.18%) in PKD2) and 
thanks to the MLPA technique 4 large deletions (4 (3.77%) in PKD1 vs 1 (9.09%) in 
PKD2) were found. 
In the table 18-24 all the LOF variants identified are listed. 
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Table 18: nonsense variants identified in PKD1 with the NGS developed method within ADPKD 
cohort. 
 
c.DNA	 Protein		 Ex	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.1477C>T	 p.Gln493*	 7	 1	 -/-	 present	study	
c.2329C>T	 p.Gln777*	 11	 1	 -/-	 present	study	
c.3250C>T	 p.Gln1084*	 14	 1	 DP/-	 (A)	
c.4494C>G		 p.Tyr1498*	 15	 1	 -/-	 present	study	
c.4797C>A	 p.Tyr1599*	 15	 1	 DP/-	  (Audrézet et al. 2012)	
c.5482C>T	 p.Gln1828*	 15	 2	 DP/-	 (Audrézet et al. 2012)	
c.5511G>A	 p.Trp1837*	 15	 1	 DP/AF	  (Rossetti et al. 2002) 
c.5884C>T	 p.Gln1962*	 15	 1	 -/-	 present	study	
c.6040C>T	 p.Gln2014*	 15	 1	 DP/-	 (Audrézet et al. 2012)	
c.6424C>T	 p.Gln2142*	 15	 1	 DP/AF	  (Rossetti et al. 2012) 
c.7126C>T	 p.Gln2376*	 17	 1	 DP/-	  (Rossetti et al. 2002) 
c.7137C>G	 p.Tyr2379*	 17	 1	 DP/-	 (Audrézet et al. 2012)	
c.7288C>T	 p.Arg2430*	 18	 1	 DP/-	  (Rossetti et al. 2012) 
c.7987C>T	 p.Gln2663*	 21	 1	 DP/-	 (Audrézet et al. 2012)	
c.8428G>T	 p.Glu2810*	 23	 1	 DP/-	  (Rossetti et al. 2012) 
c.8560C>T	 p.Gln2854*	 23	 2	 DP/-	 (Audrézet et al. 2012)	
c.8860G>T	 p.Glu2954*	 24	 1	 -/-	 present	study	
c.8972_8973insA	 p.Tyr2991*	 25	 1	 DP/-	 (Audrézet et al. 2012)	
c.9051C>A	 p.Tyr3017*	 25	 1	 -/-	 present	study	
c.9760C>T	 p.Gln3254*	 29	 2	 -/-	 present	study	
c.9852C>A	 p.Cys3284*	 29	 1	 -/-	 present	study	
c.11417G>A	 p.Trp3806*	 41	 1	 DP/-	  (Stekrova et al. 2009) 
c.11424G>A	 p.Trp3808*	 41	 1	 -/-	 present	study	
c.11614G>T	 p.Glu3872*	 42	 1	 DP/-	  (Tan et al. 2009) 
c.12168G>A	 p.Trp4056*	 45	 1	 -/-	 present	study	
c.12240G>A	 p.Trp4080*	 45	 1	 DP/-	 (A)	
 
Table 19: nonsense variants identified in PKD2 with the NGS developed method within ADPKD 
cohort. 
 
c.	DNA	 Protein	 Ex	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.916C>T	 p.Arg306*	 4	 1	 DP/-	  (Audrézet et al. 2012)	
c.1960C>T	 p.Arg654*	 9	 2	 DP/-	 (Audrézet et al. 2012)	
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Table 20: frameshift variants identified in PKD1 with the NGS developed method within ADPKD 
cohort. 
 
c.DNA	 Protein	 ex	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.484del	 p.Ala162Leufs*128	 4	 1	 -/-	 Present	Study	
c.803dup	 p.Phe269Leufs*102	 5	 1	 -/-	 Present	Study	
c.2494dup	 p.Arg832Profs*40	 11	 1	 DP/-	 (Rossetti et al. 2012)	
c.3210_3222del	 p.Tyr1071Serfs*29	 14	 1	 -/-	 Present	Study	
c.3236del	 p.Asp1079Alafs*25	 14	 1	 -/-	 Present	Study	
c.3398_3399del	 p.Val1133Glufs*2	 15	 1	 -/-	 Present	Study	
c.3735_3741del	 p.Phe1245Leufs*26	 15	 1	 -/AF	 (Carrera et al. 2016) 
c.4429del	 p.Leu1479Trpfs*55	 15	 1	 -/-	 Present	Study	
c.4631_4640del	 p.Val1544Alafs*16	 15	 1	 -/-	 Present	Study	
c.5014_5015del	 p.Arg1672fs*98	 15	 2	 DP/AF	 (Audrézet et al. 2012)	
c.5425del	 p.Ala1809Profs*27	 15	 1	 -/-	 Present	Study	
c.5536del	 p.Ser1846Alafs*103	 15	 1	 -/-	 Present	Study	
c.6016del	 p.Trp2006Glyfs*110	 15	 1	 -/-	 Present	Study	
c.8824del	 p.Leu2942Trpfs*52	 24	 1	 -/-	 Present	Study	
c.10700dup	 p.Val3568Cysfs*59	 36	 1	 -/-	 Present	Study	
c.10719_10720del	 p.Gly3574Valfs*52	 36	 1	 DP/-	 (Audrézet et al. 2012)	
c.10904del	 p.Ala3635Valfs*2	 37	 1	 -/-	 Present	Study	
c.11134del	 p.Arg3712Glyfs*114	 38	 1	 DP/AF	 (Turco et al. 1997)	
c.11635_11645del	 p.Ala3879Profs*78	 42	 1	 -/-	 Present	Study	
c.11819dup	 p.Leu3941Alafs*20	 43	 1	 -/-	 Present	Study	
c.12011dup	 p.Gln4005Alafs*152	 44	 1	 -/-	 Present	Study	
c.12232_12241del	 p.Glu4078Thrfs*117	 45	 1	 -/-	 Present	Study	
c.12308del	 p.Ala4103Valfs*95	 45	 1	 -/-	 Present	Study	
 
Table 21: indel non-frameshift variants identified in PKD1 with the NGS developed method 
within ADPKD cohort. 
 
c.DNA	 Protein		 Ex	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.2059_2064del	 p.Leu687_Phe688del	 10	 1	 -/-	 Present	Study	
c.8935_8937del	 p.Phe2979del	 24	 1	 HLP/PAF	 (Rossetti et al. 2007)	
 
Table 22: frameshift variants identified in PKD2 with the NGS developed method within ADPKD 
cohort. 
c.DNA	 Protein	 Ex	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.540dup	 p.Arg186Glyfs*32	 1	 1	 -/-	 Present	Study	
c.1449dup	 p.Ile484Tyrfs*42	 6	 1	 -/-	 Present	Study	
 
Table 23: canonical splicing site variants identified in PKD1 with the NGS developed method 
within ADPKD cohort. 
 
c.DNA	 Protein	 IVS/EX	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.9713-2A>G	 p.(?)	 IVS28	 1	 -/-	 present	study	
c.2098-2_2109del	 p.(?)	 IVS10	 1	 -/-	 present	study	
c.2986-2_2987del	 p.(?)	 IVS12/EX13	 1	 -/-	 present	study	
c.11257_11269+3del	 p.(?)	 EX39/IVS39	 1	 -/-	 present	study	
c.3161+1G>A	 p.(?)	 IVS13	 1	 -/-	 present	study	
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Table 24: canonical splicing site variants identified in PKD2 with the NGS developed method 
within ADPKD cohort. 
 
c.	DNA	 Protein	 IVS/EX	 n.	of	unrel.	patients	
PKDB/	
LOVD	 Reference	
c.1094+1_1094+4del	 p.(?)	 IVS4	 2	 HLP/AF	  (Magistroni et al. 2003)	
c.1319+1G>A	 p.(?)	 5	 1	 DP/AF	  (Magistroni et al. 2003)	
 
 
Table 18-24: tables reported all the Loss of Function mutations found in the ADPKD entire cohort divided grouped by type and 
gene. For each mutation are reported the gene, the nucleotide change in mRNA transcript (PKD1: NM_001009944.2 and PKD2: 
NM_000297.3), the aminoacidic change, the exons or IVS (intronic variant sequence number), the number of times in which the 
mutations were found in unrelated patients, the classification reported in Autosomal Dominant Polycystic Kidney Mutations 
Database (PKDB) and in Leiden Open Variation Database (LOVD3.0) and the references. Abbreviations:DP: definitely 
pathogenic; AF: affected function; HLP: High likely pathogenic; PAF: Probably Affected Function. 
 
All these definitely pathogenic variants were checked into LOVD and PKDB, two 
free databases, available online, containing a comprehensive coverage of published 
ADPKD human mutations. As the tables show, 10 (38.46%) nonsense mutations were 
novel in PKD1. In particular, the c.8860G>T, p.Glu2954*, c.9051C>A, p.Tyr3017*, 
c.2329C>T, p.Gln777* were also found in the proband affected-relatives. An 
interesting case in our familiar studies involved the c.6040C>T, p.Gln2040*, 
described in literature as a definitely pathogenic mutation (Audrézet et al 2012). 
Analyzing two healthy and four clinically affected family members, we confirmed the 
correct segregation of the mutation within only three of the four affected family 
members. The child of the proband, in fact, resulted wild type for the nonsense 
mutation but showed a similar clinical phenotype. Allele drop-out was excluded by 
using different primer pairs for LR-PCR, and a second investigation performed on the 
child excluded other pathogenic variants in PKD1 and PKD2 so further investigations 
have been advised.  
Moreover, 20 frameshift novel mutations (18 (78.26%) in PKD1 vs 2 (100%) in 
PKD2) were identified, the c.3210_3222del, p.Tyr1071Serfs*29, c.803dup, 
p.Phe269Leufs*102, c.11819dup, p.Leu3941Alafs*20, were recurrent in the proband 
affected-relatives and the c.3236del, p.Asp1079Alafs*25 resulted as a de novo in the 
proband; only 1 (50%) PKD1 novel indel non frameshift mutations c.2059_2064del, 
p.Leu687_Phe688del was identified in one of the patients and in his affected brother. 
Finally, 5 (100%) novel variants in canonical splicing site were detected in PKD1 
and, among these, the presence of the c.9713-2A>G and the c.11257_11269+3del 
were confirmed in affected relatives. 
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In order to classify all the missense variants, we combined results from known 
pathogenic variants and the current classifications (see section 3.3.6.1). 
 
Table 25: missense variants identified in PKD1 with the NGS developed method within ADPKD 
cohort. 
 
c.DNA	 Protein		 ex	
n.	of	
unrel.	
patients	
PKDB/	
LOVD	
SIFT/	
PP2	 ExAC	 Reference	
c.74G>T		 p.Gly25Val		 1	 1	 IND/-	 T/B	 -	 (A)	
c.194T>A	 p.Ile65Asn	 1	 1	 -/UNK	 D/B	 -	 (Carrera et al. 2016)	
c.230A>G	 p.Asn77Ser	 2	 1	 HLP/-	 D/B	 -	 (A)	
c.301A>G		 p.Asn101Asp	 3	 1	 HLP/-	 D/PD	 -	 (A)	
c.971G>T	 p.Arg324Leu	 5	 1	 LN/PNAF	 T/PD	 0.006	 (Rossetti et al. 2007)	
c.974A>G	 p.Tyr325Cys	 5	 1	 HLP/PAF	 D/PD	 -	 (Audrézet et al. 2012)	
c.1261C>T	 p.Arg421Cys	 6	 1	 -/AF	 D/PD	 -	 (Carrera et al. 2016)	
c.1295C>T	 p.Ala432Val	 6	 1	 HLP/-	 D/PD	 -	 (Rossetti et al. 2007)	
c.1777G>A	 p.Glu593Lys	 9	 1	 -/-	 D/PD	 -	 present	study	
c.2438G>A	 p.Cys813Tyr	 11	 1	 -/-	 D/PD	 -	 present	study	
c.2695C>G	 p.Leu899Val	 11	 1	 -/UNK	 D/PD	 0.00006	 (Carrera et al. 2016)	
c.2830C>T	 p.	Arg944Cys	 11	 1	 LP/-	 D/PD	 -	 (A)	
c.3490G>A	 p.Gly1164Arg	 15	 1	 -/-	 D/PD	 -	 present	study	
c.4628C>T		 p.Thr1543Met	 15	 1	 -/-	 T/PD	 0.00005	 present	study	
c.4856C>T		 p.Ser1619Phe	 15	 1	 LN/UNK	 D/PD	 0.0009	 (Irazabal et al. 2011)	
c.5102A>T	 p.Asn1701Ile	 15	 1	 -/-	 D/PD	 -	 present	study	
c.5830G>A	 p.Gly1944Arg	 15	 1	 IND/-	 D/PD	 0.0002	 (A)	
c.5999C>G	 p.Ser2000Cys	 15	 1	 -/-	 D/PD	 -	 present	study	
c.6070C>T	 p.Arg2024Cys	 15	 1	 -/-	 D/PD	 0.0003	 present	study	
c.6799G>C	 p.Val2267Leu	 15	 1	 -/-	 T/PD	 0.00002	 present	study	
c.6908C>T	 p.Ser2303Leu	 15	 1	 -/-	 D/PD	 0.00004	 present	study	
c.7166T>C	 p.Leu2389Ser	 17	 1	 -/-	 D/PD	 -	 present	study	
c.7535T>C	 p.Leu2512Pro	 19	 1	 -/-	 D/PD	 -	 present	study	
c.7546C>T	 p.Arg2516Cys	 19	 1	 HLP/-	 D/PD	 -	 (Cornec-Le Gall et al. 2013)	
c.7622C>T	 p.Pro2541Leu	 19	 1	 -/PAF	 D/PD	 0.0006	 (Carrera et al. 2016)	
c.7663G>A	 p.Val2555Met	 19	 1	 -/-	 D/PD	 -	 present	study	
c.7979A>G	 p.Asp2660Gly	 21	 1	 -/-	 D/PD	 -	 present	study	
c.8000C>A	 p.Ala2667Glu	 21	 1	 -/-	 D/PD	 -	 present	study	
c.8179G>C	 p.Ala2727Pro	 23	 1	 -/-	 D/B	 -	 present	study	
c.8270C>G	 p.Ser2757Cys	 23	 1	 -/-	 D/PD	 -	 present	study	
c.8293C>T	 p.Arg2765Cys	 23	 2	 Lhypo/PAF	 D/PD	 0.004	  (Rossetti et al. 2007)	
c.8311G>A	 p.Glu2771Lys	 23	 4	 HLP/-	 D/PD	 -	  (Audrézet et al. 2012)	
c.8696T>C	 p.Val2899Ala	 23	 1	 -/-	 D/PD	 -	 present	study	
c.9404	C>T	 p.Thr3135Met 	 27	 1	 LP/PAF	 D/PD	 -	  (Bataille et al. 2011)	
c.9583T>G	 p.Trp3195Gly	 28	 1	 -/-	 D/PD	 -	 present	study	
c.	9739C>T	 p.Arg3247Cys	 29	 1	 -/-	 D/PD	 0.00003	 present	study	
c.9829C>T	 p.Arg3277Cys	 29	 1	 Lhypo/PAF	 D/PD	 0.0002	  (Vujic et al. 2010)	
c.10043G>A	 p.Arg3348Gln	 30	 1	 LP/PAF	 D/PD	 -	 (Cornec-Le Gall et al. 2013)	
c.11015G>A	 p.Arg3672Gln	 37	 1	 LN/UNK	 T/PD	 0.0009	 (A)	
c.11258G>A	 p.Arg3753Gln	 39	 1	 HLP/-	 D/PD	 -	  (Rossetti et al. 2012)	
c.11390A>G	 p.Tyr3797Cys	 40	 1	 -/PAF	 D/PD	 -	 (Carrera et al. 2016)	
c.11440T>C	 p.Tyr3814His	 41	 1	 -/-	 D/PD	 -	 present	study	
c.12032A>T	 p.Gln4011Leu	 44	 1	 -/-	 D/PD	 -	 present	study	
c.12051G>C	 p.Lys4017Asn	 44	 1	 -/-	 D/PD	 0.0008	 present	study	
c.12444G>C	 p.Glu4148Asp	 45	 1	 -/-	 D/PD	 -	 present	study	
c.12460C>T	 p.Arg4154Cys	 46	 1	 LP/PAF	 D/PD	 0.009	  (Perrichot et al. 1999)	
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Table 26: missense variants identified in PKD2 with the NGS developed method within ADPKD 
cohort. 
 
c.DNA	 Protein	 Ex	
n.	of	
unrel.	
patients	
PKDB/	
LOVD	
SIFT/	
PP2	 EXAC	 REFERENZE	
c.974G>A	 p.Arg325Gln	 4	 1	 HLP/AF	 D/PD	 /	  (Bataille et al. 2011)	
c.1445T>G	 p.Phe482Cys	 6	 2	 LN/AF	 D/PD	 0.002	  (Dedoussis et al. 2008)	
c.2186T>A	 p.Leu729Gln	 11	 1	 -/-	 D/PD	 0.00002	 present	study	
c.2865G>T	 p.Met955Ile	 15	 1	 -/-	 T/B	 /	 present	study	
 
Table 25-26: all the missense variants found in the ADPKD entire cohort are reported. For each mutation the gene, the 
nucleotide change in mRNA transcript (PKD1: NM_001009944.2 and PKD2: NM_000297.3), the aminoacidic change, the exons 
or IVS (intronic variant sequence number), the number of times in which the mutations were found in unrelated patients, the 
classification reported in Autosomal Dominant Polycystic Kidney Mutations Database (PKDB) and in Leiden Open Variation 
Database (LOVD3.0), the pathogenicity prediction carried out using Polyphen 2.0 (PP2) and SIFT and the minor frequency allele 
annotated in ExAC are reported. The last column reports the references. Abbreviations: AF: affected function; HLP: High likely 
pathogenic; PAF: Probably Affected Function; LP: likely pathogenic; PNAF: potentially not affect function; Lhypo: Likely 
Hypomorphic; IND: indeterminate significance; UNK: unknown significance; LN: likely neutral; PD: Possibly Damaging; D: 
Damaging: T: tolerated; B: benign. 
 
 
In our cohort, 25 novel missense mutations (23(50%) in PKD1 vs 2 (50%) in PKD2) 
all predicted as likely pathogenic by bioinformatic tools were also detected (Table 25-
26). Among these, the c.8000C>A, p.Ala2667Glu and c.5102A>T, p.Asn1701Ile 
were also confirmed in all affected relatives and we classified them as likely 
pathogenic variants. 
The c.8293C>T, p.Arg2765Cys, c.8311G>A, p.Glu2771Lys in PKD1 and the 
c.1445T>G, p.Phe482Cys in PKD2 were found in more than one unrelated patients. 
All these three variants have already been reported in literature as associated with 
ADPKD. In particular, the PKD1 variants were all classified as potentially affected 
functions and the PKD2 variant resulted as hypomorfic and functional studies 
revealed a lower PC-2 channel function compared with controls in homozygous cells 
and heterozygous as well (Dedoussis et al 2008). 
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4.3.1.1 Cases with more than one variant in PKD1 
Although ADPKD is classically inherited as an autosomal dominant disease resulting 
from heterozygous mutations in either PKD1 or PKD2, recent and major advances in 
molecular genetic basis underline a complex inheritance pattern of ADPKD, leading 
to the discovery of hypomorphic or incompletely penetrant alleles. In our study we 
found 13 unrelated patients with more than one variant in PKD1 (Table 27). Usually, 
in cases with more than one variant, familiar study could help to understand the 
pathogenic role. In our study, unfortunately, the unavailability of sufficient affected 
family members for some cases did not allow for the in-depth study of the variant role 
in ADPKD. 
.Table 27: Cases with more than 1 variant in PKD1. 
 
n°	 Gene	
ET/	
OM
O	
c.DNA	 Protein		 EX/	IVS	
M
/
P	
SIFT/	
PP2	
PKDB/	
LOVD	 Reference	
1	 PKD1	
ET	 c.5830G>A	 p.Gly1944Arg	 15	 -	 D/PD	 IND/-	 (A)	
ET	 c.11390A>G	 p.Tyr3797Cys	 40	 -	 D/PD	 -/PAF	 (Carrera et al. 2016)	
2	 PKD1	
ET	 c.6799G>C	 p.Val2267Leu	 15	 -	 T/PD	 -/-	 present	study	
ET	 c.8311G>A	 p.Glu2771Lys	 23	 -	 D/PD	 HLP/-	 (Audrézet et al. 2012)	
3	 PKD1	
ET	 c.2098-2_2109del	 p.(?)	 IVS10	 -	 -/-	 -/-	 present	study	
ET	 c.	9739C>T	 p.Arg3247Cys	 29	 -	 D/PD	 -/-	 present	study	
4	 PKD1	
ET	 c.8270C>G	 p.Ser2757Cys	 23	 -	 D/PD	 -/-	 present	study	
ET	 c.11614G>T	 p.Glu3872*	 42	 -	 -/-	 DP/-	 (Tan et al. 2009)	
5	 PKD1	
ET	 c.3490G>A	 p.Gly1164Arg	 15	 M	 D/PD	 -/-	 present	study	
ET	 c.8293C>T	 p.Arg2765Cys	 23	 P	 D/PD	 LHypo/PAF	 (Rossetti et al. 2012)	
ET	 c.10043G>A	 p.Arg3348Gln	 30	 P	 D/PD	 LP/PAF	 (Cornec et al. 2013)	
6	 PKD1	
ET	 c.3735_3741del	 p.Phe1245Leufs*26	 15	 -	 -/-	 -/AF	 (Carrera et al. 2016)	
ET	 c.6070C>T	 p.Arg2024Cys	 15	 -	 D/PD	 -/-	 present	study	
7	 PKD1	
ET	 c.11440T>C	 p.Tyr3814His	 41	 M	 D/PD	 -/-	 present	study	
ET	 c.12032A>T	 p.Gln4011Leu	 44	 M	 D/PD	 -/-	 present	study	
8	 PKD1	
ET	 c.1477C>T	 p.Gln493*	 7	 -	 -/-	 -/-	 present	study	
ET	 c.2830C>T	 p.	Arg944Cys	 11	 -	 D/PD	 LP/-	 (A)	
9	 PKD1	
ET	 c.1777G>A	 p.Glu593Lys	 9	 -	 D/PD	 -/-	 present	study	
ET	 c.6908C>T	 p.Ser2303Leu	 15	 -	 D/PD	 -/-	 present	study	
10	 PKD1	
ET	 c.4797C>A	 p.Tyr1599*	 15	 M	 -/-	 DP/-	 (Audrézet et al. 2012)	
ET	 c.5999C>G	 p.Ser2000Cys	 15	 P	 D/PD	 -/-	 present	study	
11	 PKD1	
ET	 c.2695C>G	 p.Leu899Val	 11	 n	 D/PD	 -/UNK	 (Carrera et al. 2016)	
ET	 c.11134del	 p.Arg3712Glyfs*114	 38	 P	 -/-	 DP/AF	 (Turco et al. 1997)	
12	 PKD1	
ET	 c.230A>G	 p.Asn77Ser	 2	 -	 D/B	 HLP/-	 (A)	
ET	 c.12460C>T	 p.Arg4154Cys	 46	 -	 D/PD	 LP/PAF	 (Perrichot et al. 1999)	
13	 PKD1	 OMO	 c.9829C>T	 p.Arg3277Cys	 29	 T	 D/PD	 LHypo/PAF	
(Vujic et al. 2010)	
	
 
Table 27: table reported ADPKD unrelated cases with more than 1 variant in PKD1. For each mutation the inheritance 
(M=maternal; P=Paternal; n=de novo), the nucleotide change in mRNA transcript (PKD1: NM_001009944.2 and PKD2: 
NM_000297.3), the aminoacidic change, the exons or IVS (intronic variant sequence number), the classification reported in 
Autosomal Dominant Polycystic Kidney Mutations Database (PKDB) and in Leiden Open Variation Database (LOVD3.0), the 
pathogenicity prediction carried out using Polyphen 2.0 (PP2) and SIFT are reported. The last column reports the references. 
Abbreviations: HLP: High likely pathogenic; PAF: Probably Affected Function; PNAF: potentially not affect function; Lhypo: 
Likely Hypomorphic; IND: indeterminate significance; PD: Possibly Damaging; D: Damaging: T: tolerated; B: benign. 
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Thanks to the collaboration of family members we were able to identify pathogenic 
variants in families 5, 7,10 and 11. 
The NGS protocol detected in proband 5 (Figure 17) two described causative variants 
the c.8293C>T, p.Arg2765Cys and c.10043G>A, p.Arg3348Gln and the novel 
c.3490G>A, p.Gly1164Arg (Table 25). The two causative variants were found in cis 
in his healthy brother and father, while the novel variant was inherited by his affected 
mother. This family study allowed us to establish a causative role of the variants 
found in the present study and to conclude that the compound heterozygous with the 
other variants can result in a more severe phenotype. The two variants in cis were not 
sufficient for the phenotype manifestation but can act as disease-modifying. However, 
the lack of accurate renal ultrasound reports of “healthy” relatives did not allow the 
exclusion of a mild phenotype.  
Another disease-modifying variant was the c.5999C>G, p.Ser2000Cys. In family 10 
(Figure 17), the proband showed the c.5999C>G, p.Ser2000Cys in compound 
heterozygous with a truncated mutation inherited by the affected mother. Although 
the missense variant alone was not sufficient for the phenotype manifestation in the 
father, the coinheritance occurred as a more severe disease. 
In family 11 (Figure 17) the proband inherited the frameshift mutation c.11134del, 
p.Arg3712Glyfs*114 from his affected father but showed an ARPKD phenotype. The 
molecular analysis of PKHD1 excluded molecular defects in this gene but we found 
an addictional de novo causative mutations in PKD1, the c.2695C>G, p.Leu899Val. 
This second variant, in trans with the inactivated-PKD1 allele caused in the proband 
an in-utero-onset of ADPKD. The proband in family 7 presented two different novel 
mutations, both of them predicted as potential pathogenic by bioinformatics tools. 
These two variants, the c.11440T>C, p.Tyr3814Hys and the c.12032A>T, 
p.Gln4011Leu resulted inherited both from her affected mother, so the cis 
configuration did not help us define which of them was the causative one. Finally, an 
interesting case was represented by the patients 13 that showed an ARPKD phenotype 
but resulted wild type for the molecular screening of PKHD1. This patient presented 
the homozygosity of an hypomorphic allele c.9829C>T, p.Arg3277Cys in PKD1. 
Rossetti et al. reported that the heterozygous mutation alone may result in mild cystic 
disease, while the homozygosity can cause an ARPKD-like phenotype (Rossetti et al 
2009). 
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Family 5 
 
Family 10 
 
Family 11 
 
Figure 17: the pedigree of families 5, 10 and 11 are represented. Below each family tree the mutations visualized by IGV are 
reported. Probands are indicated by the arrow.  
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4.3.2 Molecular screening of PKHD1 
The mutational screening of PKHD1 gene was performed on a cohort of 28 unrelated 
patients divided in two groups (A and B): Group A consisted of 15 unrelated probands 
with clinical suspect of ARPKD, including 2 fetuses from terminated pregnancy and 2 
severely affected newborns who died shortly after birth; Group B counted 13 
unrelated healthy carriers, as parents of affected ARPKD fetuses. All the fetuses from 
terminated pregnancies presented oligo/anhydramnios and renal pathology including 
dilated tubules and/or collecting ducts, changed kidney size and bilaterally enlarged 
hyperechogenic kidneys. 
In table 28 and in the pie charts in figure 18 are reported the total and the novel 
variants found in this study divided for type. The frequency of the total variant is 
calculated on the total number and the frequency of the novel is calculated as the ratio 
between the novel and the total for each type.  
 
Table 28: all identified mutations in PKHD1 with the NGS method. 
 
TYPE	
PKHD1	
TOTAL	 NOVEL	
NONSENSE	 7(18.91%)	 4(57.14%)	
FRAMESHIFT	 4(10.81%)	 2(50%)	
INDEL	NON	FRAMESHIFT	 1(2.70%)	 1(100%)	
CANONICAL	SPLICING	 1(2.70%)	 1(100%)	
MISSENSE	 24(64.86%)	 10(41.66%)	
TOTAL	 37	 18(48.64%)	
	
 
Table 28: all mutations found, in this study, in PKHD1 sorted by type. The total variant type percentage is calculated by 
dividing the number of each variant type by the total variants, while the percentage for each type of novel is calculated to each 
variant type. 
 
 
 
  
Figure 18: The pie charts reports all the mutations found in PKHD1 in ARPKD cohort on the left, and the novel variants 
identified, on the right. 
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In total, 37 different variants, almost evenly distributed throughout the entire gene 
transcript, were detected. 13 were loss of function (18.91% (n=7) nonsense, 10,81% 
(n=4) frameshift and 2.70% (n=1) indel non frameshift and 2.70% (n=1) variant in 
canonical splicing site) and 64.86% (n=24) were missense mutations. 
All the variants were checked against the mutation databases for ARPKD and LOVD 
3.0 and for each variant the minor frequency allele was obtained by ExAC browser. 
The tables below reports the mutation divided by type in detail. All the missense were 
submitted to predictional pathogenicity tools SIFT and POLYPHEN 2.0 in order to 
achieve a preliminary pathogenic classifications. 
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Table 29: nonsense variants identified in PKHD1 with the NGS developed method within 
ARPKD cohort. 
 
c.DNA	 Protein		 ex	
n°	of	
unrel	
patients	
Humgen/
LOVD	 EXAC	 Reference	
c.370C>T	 p.Arg124*	 5	 1	 P/AF	 0.00002	 (Bergmann et al. 2005)	
c.4417C>T	 p.Gln1473*	 32	 1	 -/-	 /	 present	study	
c.6472G>T	 p.Glu2158*	 39	 1	 -/-	 /	 present	study	
c.7328T>G	 p.Leu2443*	 46	 1	 -/-	 /	 present	study	
c.8470C>T	 p.Gln2824*	 54	 1	 -/-	 /	 present	study	
c.10174C>T	 p.Gln3392*	 61	 1	 P/AF	 0.000009	 (Loosekoot et al. 2005)	
c.11314C>T	 p.Arg3772*	 63	 1	 P/AF	 /	 (Bergmann et al. 2004)	
 
Table 30: frameshift variants identified in PKHD1 with the NGS developed method within 
ARPKD cohort. 
 
c.DNA	 Protein		 ex	
n°	of	
unrel	
patients	
Humgen/	
LOVD	 EXAC	 Reference	
c.1197delC	 p.Leu400Cysfs*13	 15	 1	 -/-	 0.000008	 present	study	
c.5895dup		 p.Leu1966Thrfs*4	 36	 2	 P/AF	 /	  (Gunay-Aygun et al. 2010)	
c.6390dup	 p.Thr2131Hisfs*17	 39	 1	 -/-	 /	 present	study	
c.10856del	 p.Lys3619Serfs*7	 61	 1	 P/AF	 /	  (Rossetti et al. 2003)	
 
Table 31: indel non-frameshift variants identified in PKHD1 with the NGS developed method 
within ARPKD cohort. 
 
c.DNA	 Protein		 ex	
n°	of	
unrel	
patients	
Humgen/LOV
D	 EXAC	 Reference	
c.9708_9737del	 p.Arg3237_Pro3246del	 58	 1	 -/-	 /	 present	study	
 
Table 32: canonical splicing site variants identified in PKHD1 with the NGS developed method 
within ARPKD cohort. 
 
cDNA	 Protein		 IVS	 n°	of	unrel	patients	 Humgen/LOVD	 EXAC	 Reference	
c.8555-2A>C	 p.(?)	 54	 1	 -/-	 -	 present	study	
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Table 33: Missense variants identified in PKHD1 with the NGS developed method within 
ARPKD cohort. 
 
c.DNA	 Protein		 ex	
n°	of	
unrel	
pat	
Humgen
/LOVD	
SIFT/	
PP2	 EXAC	 Reference	
c.1A>G	 p.Met1Val	 2	 2	 -/-	 -/-	 -	 present	study	
c.107C>T	 p.Thr36Met	 3	 1	 PD/-	 D/PD	 0.0005	  (Loosekoot et al. 2005)	
c.664A>G	 p.Ile222Val	 9	 1	 PD/NAF	 T/B	 0.0001	  (Loosekoot et al. 2005)	
c.1736C>T	 p.Thr579Met	 19	 2	 POL/-	 D/P	 0.02	  (Loosekoot et al. 2005)	
c.2171C>G	 p.Pro724Arg	 22	 1	 PD/NAF	 D/P	 -	 (Gunay-Aygun et al. 2010)	
c.2702A>C	 p.Asn901Thr	 25	 1	 PD/-	 D/PD	 0.000008	 unpublish	data	
c.2929A>T	 p.Asn977Tyr		 27	 1	 -/-	 T/D	 0.000008	 present	study	
c.3407A>G		 p.Tyr1136Cys	 30	 1	 PD/UNK	 T/PD	 0.008	 (Loosekoot et al. 2005)	
c.3686G>C	 p.Trp1229Ser	 32	 1	 nd/-	 T/B	 0.003	  (Suzuki et al. 2006)	
	c.4292G>A 	 p.Cys1431Tyr		 32	 1	 -/-	 D/PD	 0.00003	 present	study	
c.4519C>G	 p.Gln1507Glu	 32	 1	 -/-	 T/B	 0.00003	 present	study	
c.4870C>T	 	p.Arg1624Trp	 32	 1	 PD/AF	 T/D	 0.0002	  (Onuchic et al. 2002)	
c.5068T>C	 p.Ser1690Pro	 32	 1	 -/-	 T/D	 -	 present	study	
c.5336A>G	 p.Asn1779Ser	 33	 1	 -/-	 T/PD	 -	 present	study	
c.5830G>A	 p.Asp1944Asn	 36	 1	 -/-	 D/P	 0.00002	 present	study	
c.8206T>G	 p.Trp2736Gly	 52	 2	 nd/AF	 D/B	 0.00002	  (Denamur et al. 2010)	
c.8518C>G	 	p.Arg2840Gly	 54	 1	 -/-	 T/B	 0.00003	 present	study	
c.8521A>G	 p.Met2841Val	 54	 1	 PD/NAF	 T/B	 0.003	  (Loosekoot et al. 2005)	
c.8581A>G	 p.Ser2861Gly	 55	 1	 PD/NAF	 T/B	 0.003	 (Gunay-Aygun et al. 2010)	
c.8606C>A	 p.Thr2869Lys	 55	 1	 POL/AF	 D/PD	 0.009	  (Rossetti et al. 2003)	
c.9163G>T	 p.Gly3055Cys	 58	 1	 -/-	 D/D	 -	 present	study	
c.9189C>A	 p.Asn3063Lys	 58	 1	 -/-	 D/D	 -	 present	study	
c.9370C>T	 p.His3124Tyr		 58	 1	 PD/AF	 D/D	 -	  (Furu et al. 2003)	
c.10444C>T	 p.Arg3482Cys	 61	 2	 PD/AF	 D/D	 0.00006	  (Bergmann et al. 2005)	
 
 
Table 29-33: reported all the missense variants found in the ADPKD entire cohort. For each mutation the gene, the nucleotide 
change in mRNA transcript (PKHD1: NM_138694), the aminoacidic change, the exons or IVS (intronic variant sequence 
number), the number of times in which the mutations were found in unrelated patients, the classification reported in Autosomal 
Recessive Polycystic kidney disease database (Humegene) and in Leiden Open Variation Database (LOVD3.0), the 
pathogenicity prediction carried out using Polyphen 2.0 (PP2) and SIFT and the minor frequency allele reports in ExAC are 
reported. The last column reports the references. Abbreviations: AF: affected function; NAF: Not Affected Function; nd: 
classification not available; UNK: unknown significance; POL: Polymorphism; PD: Possibly Damaging; D: Damaging: T: 
tolerated; B: benign. 
	
Overall, 18 (48.64%) novel variants were identified in this study, 44.4% (n=8) were 
classified as pathogenic because predicted to caused a non-functional proteic product 
(4 nonsense, 2 frameshift, 1 indel non frameshift and 1 canonical splice site variant). 
The majority of mutant alleles were unique for each family, however 5 variants, the 
frameshift mutation c.5895dup, p.Leu1966Thrfs*4, and the 4 missense variants 
c.1A>T p.Met1Val; c.1736C>T, p.Thr579Met; c.8206T>G, p.Trp2736Gly 
c.10444C>T, p.Arg3482Cys appeared at least 2 families. 
In Group A (Table 34), 14 of the 15 probands presented at least two pathogenic or 
probably pathogenic mutations in compound heterozygous status, one of these 
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patients (#5) presented 3 variants, however we could not establish if they were in cis 
or in trans configuration. 
40% (n=6) of patients with two causal mutations harbored a combination of a 
missense and chain-terminating mutation while the combination of two missense or 
two truncating mutations was accounted for the 33.33% (n=5) and the 6,67% (n=1), 
respectively.  
Group B (Table 35) counted 12 potentially healthy carriers in 6 non-consanguineous 
marriage, with at least one child affected by ARPKD or with termination of 
pregnancies for oligo/anhydramnios and fetus renal pathologies, and one with a 
previously molecular diagnosis of healthy carriers. In all but 3 cases, at least one 
causative variant was identified. 3 cases reported a truncating or frameshift mutations, 
2 showed a nucleotide change in the initiation codon and, finally, 5 patients presented 
at least one missense variant. All the missense variants were described in either one of 
the mutational databases mentioned above. 
In the mother of family 16, 2 missense variants were identified, the c.10444C>T 
p.Arg3482Cys was predicted as damaging, whereas the c.8581A>G p.Ser2861Gly 
was predicted as tolerated by prediction tools. Both parents of this family were 
healthy obligate carriers of an ARPKD defect because their fetuses in the two 
terminated pregnancies presented ARPKD features. The presence of c.10444C>T, 
p.Arg3482Cys and the paternal c.1A>G, p.Val1Met were confirmed in both fetal 
DNAs extracted from conserved tissues sample. 
 
The overall detection rate amounts to 93.33% in Group A and to 77% in Group B and 
the overall detection rate for the entire patient cohort is 85.7%. 
 
For all cases considered wild type for molecular defects in PKHD1, the investigation 
of large genomic rearrangement is recommended. 
 
 
 67 
 
Table 34: Summary of mutations and clinical phenotype found in Group A. 
#	unrel	
patient	
Ex/	
IVS	 c.DNA	 Protein		 M/P	
age	of	
diagnosis/	
Death	
Info	 Reference	
1	
32	 c.4870C>T	 	p.Arg1624Trp	 M	
perinatal	 renal	echogé/	brohter	ARPKD	(†21dd)/mother	healty	ARPKD	carrier	 (Onuchic et al. 2002) 	
61	 c.10444C>T	 p.Arg3482Cys	 P	 (Bergmann et al. 2005)	
2	
54	 c.8518C>G	 	p.Arg2840Gly	 P	 infantil	(4y)	
/†	(34y)	 renal	and	hepatic	echogé/HSM/HTN/no	familiarity	for	ARPKD	
present	study	
61	 c.10856del	 p.Lys3619Serfs*7	 M	 (Rossetti et al. 2003)	
3	
30	 c.3407A>G		 p.Tyr1136Cys	 -	
Childhood	
(15y)	 	bilatera	renal	cysts/poor	cortico-medullary	differentiation	
 (Loosekoot et al. 2005)	
32	 	c.4292G>A 	 p.Cys1431Tyr		 -	 present	study	
36	 c.5895dup		 p.Leu1966Thrfs*4	 -	 (Gunay-Aygun et al. 2010)	
4	
33	 c.5336A>G	 p.Asn1779Ser	 P	 perinatal/	
†(2dd)	 OH/renal	and	hepatic	echogé	
present	study	
54	 c.8470C>T	 p.Gln2824*	 	M	 present	study	
5	
25	 c.2702A>C	 p.Asn901Thr	 P	 Childhood	
(11y)	
bilatera	renal	cysts/poor	cortico-medullary	
differentiation/dialysis/brother	with	ARPKD	
unpublish	data	
58	 c.9189C>A	 p.Asn3063Lys	 	M	 present	study	
6	
36	 c.5830G>A	 p.Asp1944Asn	 M	
infantil	(2y)	 renal	and	liver	echogé	bilatera	renal	cysts/poor	cortico-medullary	differentiationdialysis/brother	with	ARPKD	
present	study	
52	 c.8206T>G	 p.Trp2736Gly	 P	 (Denamur et al. 2010)	
7	
32	 c.4417C>T	 p.Gln1473*	 P	 perinatal	
(4m)	
bilatera	renal	cysts/poor	cortico-medullary	differentiation/renal	and	
hepatic	echogé	
present	study	
32	 c.5068T>C	 p.Ser1690Pro	 M	 present	study	
8	
27	 c.2929A>T	 p.Asn977Tyr		 P	 perinatal	
(7m)	
bilatera	renal	cysts/poor	cortico-medullary	differentiation/renal	and	
hepatic	echogé/KTX	
present	study	
58	 c.9370C>T	 p.His3124Tyr		 M	 (Furu et al. 2003)	
9	
30	 c.3385G>A	 p.Gly1129Arg	 	M	
infantil	(1y)	 bilatera	renal	cysts/poor	cortico-medullary	differentiation/renal	and	hepatic	echogé	
present	study	
58	 c.9708_9737del	 p.Arg3237_Pro3246del	 	P	 present	study	
10	
IVS	54	 c.8555-2A>C	 p.(?)	 M	
CVS/TOP	 OH	
present	study	
58	 c.9163G>T	 p.Gly3055Cys	 P	 present	study	
11	
22	 c.2171C>G	 p.Pro724Arg	 	M	
infantil	(6y)	 renal	and	hepatic	cysts/brother	with	ARPKD/healty	consanguineous	parents	
 (Gunay-Aygun et al. 2010)	
39	 c.6472G>T	 p.Glu2158*	 P	 present	study	
12	 32	 c.3686G>C	 p.Trp1229Ser	 M	 perinatal/	†	28gw	 OH/HSM/renal	and	liver	echogé	
 (Suzuki et al. 2006)	
54	 c.8521A>G	 p.Met2841Val	 P	 (Sharp et al 2005)	
13	
39	 c.6390dup	 p.Thr2131Hisfs*17	 M	
CVS/TOP	 OH	
present	study	
46	 c.7328T>G	 p.Leu2443*	 P	 present	study	
14	
9	 c.664A>G	 p.Ile222Val	 M	 perinatal	
(7m)	
bilatera	renal	cysts/poor	cortico-medullary	differentiation/renal	and	
hepatic	echogé		
(Ward et al. 2002)	
36	 c.5895dup		 p.Leu1966Thrfs*4	 P	 (Ward et al. 2002)	
15	 5	 c.370C>T	 p.Arg124*	 	-	 Adolescent	(11y)	 bilateral	renal	cortico-medullary	cysts		 (Bergmann et al. 2005)	
 
 
Table 34: all mutations found in unrelated patients of ARPKD cohort (GroupA). For each patients the nucleotide change mutations in mRNA transcript (PKHD1: NM_138694), the aminoacidic change, the exons or 
IVS (intronic variant sequence number), the segregational study results, the patient phenotype and clinical informations are reported. The last column reports the references. Abbreviations: M:maternal; P:paternal; † 
deceased; y:years; dd: days; m:month; gw:gestational week; CVS/TOP: prenatal diagnosis after chorionic villus sampling (CVS) based on haplotyping with subsequent termination of pregnancy (TOP), echogé: 
increased echogenicity, HSM:hepatosplenomegaly; HTN: ipertension; KTX:kidney transplantions; OH:oligohydramnios;  
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Table 35: Summary of mutations and clinical phenotype found in Group B. 
 
#family/	
M/F	 	info	 c.DNA	 Protein		 ex	
HUMGEN/	
LOVD	
SIFT/	
PP2	 Reference	
16.F	
2	TOP	
c.107C>T	 p.Thr36Met	 3	 PD/-	 D/PD	 (Bergmann et al. 2005)	
16.M	 c.8581A>G	 p.Ser2861Gly	 55	 PD/NAF	 T/B	 (Furu et al. 2003) 
c.10444C>T	 p.Arg3482Cys	 61	 PD/AF	 D/PD	 (Bergmann et al. 2005)  
17.M	
2	TOP/	
1child	
ARPKD	
(†6dd)	
c.8206T>G	 p.Trp2736Gly	 52	 nd/AF	 D/B	  (Denamur et al. 2010) 
17.F	 c.1A>G	 p.Met1Val	 2	 -	 D/PD	 present study 
18.M	 1	
TOP/OH	
c.11314C>T	 p.Arg3772*	 63	 PD/AF	 -/-	  (Bergmann et al. 2004) 
18.F	 c.10174C>T	 p.Gln3392*	 61	 PD/AF	 -/-	  (Loosekoot et al. 2005)	
19.M	 healthy	carrier	 c.1197delC	 p.Leu400Cysfs*13	 15	 -	 -/-	 present	study	
20.F	 1	child	
with	
ARPDK	
c.1736C>T	 p.Thr579Met	 19	 POL/-	 D/PD	  (Loosekoot et al. 2005)	
20.M	 -	 -	 -	 -	 -	 -	
21.M	 1	TOP/	
OH	
c.8606C>A	 p.Thr2869Lys	 55	 POL/-	 D/PD	  (Bergmann et al. 2005)	
21.F	 -	 -	 -	 -	 -	 -	
22.M	 1	TOP/	
OH	
c.1A>G	 p.Met1Val	 2	 -	 D/PD	 present	study	
22.F	 -	 -	 -	 -	 -	 -	
 
 
Table 35: all mutations found in healthy carriers of ARPKD cohort (GroupB). For each subject the number of family, the 
clinical family informations, the nucleotide change mutations in mRNA transcript (PKHD1: NM_138694), the aminoacidic 
change, the exons or IVS (intronic variant sequence number), the classification reported in Autosomal Recessive Polycystic 
kidney disease database (Humegene) and in Leiden Open Variation Database (LOVD3.0), the pathogenicity prediction carried 
out using Polyphen 2.0 (PP2) and SIFT are reported. The last column reports the references. Abbreviations: M:mother; F:father ; 
TOP: prenatal diagnosis termination of pregnancy; OH:oligohydramnios; AF: affected function; NAF: Not Affected Function; 
nd: classification not available; POL: Polymorphism; PD: Possibly Damaging; D: Damaging; T: tolerated; B: benign. 
 
4.4 Time and cost analysis 
The NGS-based developed protocols turned out to be both faster and cost-saving 
compared to the traditional Sanger sequencing while allowing us to obtain rapid 
medical reports for PKD patients in just a few weeks. 
In this section we will compare the conventional Sanger sequencing and the NGS 
method analyzing reagent costs and their respective labor time to reach a complete 
molecular diagnosis of ADPKD or ARPKD patients (Table 36).  
According to our experience, by mixing barcoded-libraries obtained from the two 
differential developed protocols, we were able to obtain the simultaneous screening of 
PKD1 and PKD2 analyzing 16 patients per run. Using a 318v2 chip we reached an 
average coverage of ≥ 300X for all the target regions in all the 16 submitted patients, 
which was sufficient to ensure a complete genotyping of the two ADPKD causative 
 69 
genes. As the PKHD1 transcript gene is larger compared to PKD1 and PKD2 
transcripts we decided to mixing barcoded-libraries of maximum 12 patients in order 
to reach an average coverage ≥ 300X for all the targets, as well.  
As table 36 shows, up to 16 ADPKD patients can be genotyped with our NGS 
protocols at reagent costs of € 250  per patient compared with €1250  per patient 
using the current Sanger sequencing method. The same cost reduction is applicable 
for PKHD1 NGS protocol. 
Although the hands-on time required for setting up the LR-PCR reactions (in the case 
of PKD1), preparing the library, and sequencing still requires approximately 1 week, 
data analysis is considerably faster with NGS than with the Sanger method and can be 
completed in only a few hours without the need for expensive computer clusters and 
making it attractive to the standard diagnostic laboratory. 
 
Table 36: comparison of sequencing reagents costs and time of labor for Sanger sequencing and 
NGS 
 
	
ADPKD		
(PKD1/PKD2)	
ARPKD		
(PKHD1)	
		
Sanger	
Sequencing	 NGS	
Sanger	
Sequencing	 NGS	
Patients	per	run	 1	 16	 1	 12	
Costs	
(per	patients)	 1.250	€	 250	€	 1.100	€	 194	€	
Labor-time		
(per	patients)	 ≥	15dd	 8-10dd	 ≥	15dd	 6-8dd	
 
 
Table 36: comparison of sequencing reagents costs and time of labor necessary to obtain a complete genotyping for ADPKD and 
ARPKD causative genes with NGS protocols and traditional Sanger sequencing. Abbreviations: dd: days. 
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5. CONCLUSIONS 
The NGS differential protocols and the data analysis pipeline developed in this study 
for the molecular screening of PKD-causative genes showed an enhanced sensitivity 
compared to conventional diagnostic techniques. 
In particular, the association between the alternative libraries construction protocol 
developed for PKD1, and the our artificial reference genome created for variant 
calling process, allowed us to obtain substantial improvement of sensibility and 
specificity for PKD1 screening and allowing us to overcome the pseudogene issues.  
The NGS assays, preformed on the previously genotyped cohorts that had been 
received a molecular diagnosis for ADPKD and ARPKD by Sanger sequencing, 
allowed for the correct detection of all the mutations previously identified. For 
ADPKD patients, the NGS test identified all 20 mutations (19 in PKD1 and 1 in 
PKD2), including a repetitive variant in two unrelated patients demonstrating 
repeatability and reproducibility. In ARPKD validation cohort the individuations of 
additional variants in six patients suggested a greater sensitivity compared to 
conventional sequencing. 
 
In the total cohort (n=125) of patients with suspicions of ADPKD phenotype, the 
NGS method in association with MLPA assay identified molecular defects in 90.4% 
(n=113) of the patients, 87.6% (n=99) presented mutations in PKD1 while 12.4% 
(n=14) in PKD2. In 5 of the 12 patients found to be mutation-negative by NGS, the 
MLPA assay identified large genomic rearrangement. The combination of these two 
methods achieved a complete and accurate genetic test suitable for ADPKD 
diagnostic practice. Among all the pathogenic variants found, 58.11% (61 in PKD1 vs 
5 in PKD2) resulted previously undescribed: 41 were loss of function that we 
classified as pathogenic and 25 missense variants that we classified as likely 
pathogenic or VUS. 
The failure to find pathogenic mutations in the remaining 9.6% (n=12) of ADPKD 
families may be accounted for by the following, not mutually exclusive, reasons. 
First, the intronic regions, promoters and 5′- and 3′-untranslated regions of both the 
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PKD1 and PKD2 loci have never been systematically analyzed in literature, therefore 
no functional studies were available for non-coding variants in these particular 
regions. Second, coding variants currently classified as nonpathogenic, including 
silent mutations and some missense mutations, may be of pathogenic relevance 
through modulation of mRNA splicing and/or stability; this possibility has not been 
systematically tested to date. Third, some “ADPKD” cases may have been wrongly 
diagnosed. Finally, the existence of a third ADPKD locus cannot be excluded. 
In the ARPKD cohort, the molecular screening correctly identified two mutations in 
compound heterozygous status in 14 patients in Group A, whereas in the healthy 
carriers cohort (Group B) at least one causative mutation was identified in all but 
three cases, demonstrating an overall detection rate of 85,7%. In those cases where 
less than two mutations were found on the NGS in probands cohort and in the healthy 
carriers resulting wild type for the mutational screening the MLPA assay for the 
investigation of large genomic rearrangement is recommended. 
 
In conclusion, the NGS-based genetic analysis for ADPKD and ARPKD is a highly 
accurate and reliable approach for mutation analysis achieving high sensitivity and 
improved intronic coverage, in particular for PKD1 screening, with a faster 
turnaround time and lower cost in comparison to Sanger sequencing. 
NGS would be an appropriate new standard for clinical genetic testing of polycystic 
kidney disease. 
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